Is Current Fragile X Syndrome Counseling Enough? Expanding the Clinical Phenotype of Fragile X in Premutation And Intermediate Allele Carriers by Saadat Girnary, Zahra




Is Current Fragile X Syndrome Counseling
Enough? Expanding the Clinical Phenotype of
Fragile X in Premutation And Intermediate Allele
Carriers
Zahra Saadat Girnary
University of South Carolina
Follow this and additional works at: https://scholarcommons.sc.edu/etd
Part of the Medical Genetics Commons
This Open Access Dissertation is brought to you by Scholar Commons. It has been accepted for inclusion in Theses and Dissertations by an authorized
administrator of Scholar Commons. For more information, please contact dillarda@mailbox.sc.edu.
Recommended Citation
Saadat Girnary, Z.(2018). Is Current Fragile X Syndrome Counseling Enough? Expanding the Clinical Phenotype of Fragile X in Premutation
And Intermediate Allele Carriers. (Doctoral dissertation). Retrieved from https://scholarcommons.sc.edu/etd/4474
IS CURRENT FRAGILE X SYNDROME COUNSELING ENOUGH? EXPANDING THE 
CLINICAL PHENOTYPE OF FRAGILE X IN PREMUTATION AND INTERMEDIATE 




Zahra Saadat Girnary 
 
Bachelor of Science 
University of North Carolina at Chapel Hill, 2014 
 
Bachelor of Arts 




Submitted in Partial Fulfillment of the Requirements 
 




School of Medicine 
 






Crystal Hill-Chapman, Director of Thesis 
 
Jessica Klusek, Reader 
 
Allyn McConkie-Rosell, Reader 
 
Cheryl L. Addy, Vice Provost and Dean of the Graduate School
ii 




 For mummy and papa, for without you and your sacrifices, my dream of being a 
genetic counselor would have never been discovered, let alone pursued or accomplished. 
iv 
ACKNOWLEDGEMENTS
 I would like to thank my thesis committee members for providing me with guidance 
and support throughout this process – it has been a challenge, but it feels great to be done! 
To the team at USC – thank you for believing in me and helping me on my way to becoming 
the best counselor that I know I can be. These past two years have provided me with an 
open and accepting environment which has allowed me to thrive and learn to stand on my 
own two feet, and I cannot wait to apply what I have learned into helping others. To my 
classmates – I have absolutely LOVED sharing this experience with you and I look forward 
to our paths crossing again as colleagues so soon! You made my move away from home 
so easy and I have loved all of the trivia, the movie nights, the tea, the laughs, and the 
memories. To my friends and family, I appreciate you for listening about my long days in 
clinic, the stress regarding exams and nervousness in seeing patients, the tears about 
patients that I’ll never forget, as well as the successes (e.g. that time where a patient told 
me that I was a “rising star”) – you have allowed me to share with you an important and 
integral part of my life and for that, I’ll be forever grateful. Lastly, thank you to my parents 




Fragile X syndrome (FXS) is caused by a triplet repeat expansion on the FMR1 
gene. Individuals with >200 repeats have FXS, while individuals between 45-54 and 55-
200 repeats have the FMR1 intermediate allele and premutation, respectively. FXS is 
characterized by autism and intellectual disability while the premutation is associated with 
fragile X-associated tremor/ataxia syndrome (FXTAS) and fragile X-associated primary 
ovarian insufficiency (FXPOI). However, recent research shows that the premutation may 
be associated with psychiatric manifestations. Currently, there are no established clinical 
features associated with the intermediate allele. 
This study sought to 1) study knowledge regarding FXTAS, FXPOI, as well as the 
potential for psychiatric manifestations in individuals with the premutation; 2) study which 
features, if any, intermediate allele carriers exhibit, and 3) learn which resources are most 
helpful for FXS. Participants were recruited through online Facebook groups and 
completed one of two surveys. Results showed that 1) individuals in both groups 
overestimated their chances for FXS-related disorders; 2) significantly more individuals 
with the intermediate allele experienced depression/anxiety than expected; and 3) the most 
helpful resources for learning about FXS were internet websites and conversations with 
health providers and other individuals with the FMR1 premutation. These findings reveal 
that genetic counselors should place more emphasis on the genetics of FXS and its 
associated phenotypes to both groups and offer both traditional sources of support as well 
as referral to Facebook groups to facilitate conversations with others in similar situations. 
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1.1 FRAGILE X SYNDROME OVERVIEW 
Fragile X syndrome (FXS), one of the leading causes of X-linked intellectual 
disability and autism, affects between 1/4,000 to 1/7,000 males and between 1/8,000 to 
1/11,000 females (Cornish, Turk, & Hagerman, 2008; Fu et al., 1991; Hunter et al., 2014; 
Turner, Webb, Wake & Robinson, 1996). It is caused by an expansion of a cytosine-
guanine-guanine (CGG) trinucleotide repeat in the 5’ untranslated region of the Fragile X 
Mental Retardation 1 (FMR1) gene located on the X chromosome (Verkerk et al., 1991). 
FXS is inherited in an X-linked manner, meaning that it is transmitted from one generation 
to the next on the X chromosome. This means that none of the sons of a man with the 
premutation will inherit said premutation while all of his daughters will inherit the 
premutation, as males give their only X chromosome to their daughters and their Y 
chromosome to their sons. Additionally, females with the premutation are at an increased 
risk to have sons and/or daughters affected by FXS due to maternal anticipation, meaning 
that the repeat has a likelihood of expanding from a premutation allele to a full mutation 
when passed from mother to child (Bourgeois et al., 2009; Fu et al., 1991), with larger 
alleles at increased risk for expansion.  
The trinucleotide expansion is located in a region of the DNA that is neither 
transcribed into RNA nor translated into a protein, so it has no effect on the structure or the 
function of the FMR1 protein product. Instead, a large enough expansion (>200 CGG 
2 
repeats) leads to hypermethylation of an adjacent CpG island and causes silencing of the 
FMR1 gene.  When this gene is silenced, there is no production of the Fragile X Mental 
Retardation Protein (FMRP), a product necessary for healthy brain maturation, learning, 
and memory (Schneider, Hagerman & Hessl, 2009; Sidorov, Auerbach & Bear, 2013). In 
contrast, having fewer than 200 CGG repeats does not lead to hypermethylation of the 
nearby CpG island, and thus does not lead to the intellectual disability phenotype. Instead, 
the symptoms that we see vary from what is observed in traditional FXS and are described 
in further detail below. 
The clinical phenotype of FXS varies depending on the number of CGG repeats 
observed in an individual, and these are summarized in Table 1.1 (Biancalana, Glaeser, 
McQuaid, & Steinbach, 2015; Debrey et al., 2016; Usdin et al., 2014). Males and females 
with greater than 200 CGG repeats are said to have FXS while individuals with 55-200 and 
45-54 repeats are said to have the FMR1 premutation and intermediate allele, respectively. 
Traditionally, having fewer than 45 CGG repeats lead to no clinical manifestations and is 
considered phenotypically “normal.” 
While having >200 repeats leads to FXS, the clinical presentation between the two 
sexes can vary. This is because males only have one X chromosome, and a mutated X 
chromosome in males is sufficient to cause the condition. However, since females have 
two X chromosomes, one deficient copy of the FMR1 gene on one chromosome is in some 
ways “masked” by a working copy on the other chromosome. These females can show 
anywhere from mild to severe symptoms of the phenotype associated with the full mutation 
due to a phenomenon called skewed X-inactivation, which means that the ratio of cells 
containing the X chromosome with the functional copy of the FMR1 gene compared to the 
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cells containing the X chromosome with the mutated copy of the FMR1 gene is not equal. 
In general, it is thought that 1/3 of females with FXS have no symptoms, 1/3 have learning 
disabilities, and 1/3 have intellectual disability, but there are no definite or concrete 
numbers supporting this (Fragile X Syndrome, 2017). In light of all of the ongoing 
research, it is important to note that the spectrum of severity varies in both males and 
females, with the latter showing even more clinical variability ranging from mild to severe 
involvement.  
Having >200 CGG repeats at the 5’ end of the FMR1 gene leads to abnormal 
methylation of a nearby FMR1 CpG island. These islands are located near the “beginning” 
of the coding region of the gene, and whether or not this area is methylated determines 
whether or not the gene is transcribed, or “read” to eventually be made into a protein. This 
abnormal methylation leads to an absence of FMR1 transcription and ultimately leads to 
the phenotype that we see in affected individuals, which is described in further detail below 
(Sutcliffe et al., 1992). Males with a full mutation (as defined as having >200 CGG repeats) 
show several clinical features, including moderate intellectual disability, and autism 
spectrum disorder (ASD). Among individuals with FXS, rates for ASD are roughly 60% 
for males and 14.3% for females (Klusek, Martin, & Losh, 2014). Individuals with both 
FXS as well as ASD have more severe behavioral problems, such as attention deficit 
hyperactivity disorder (ADHD), than individuals with FXS alone (Niu et al., 2017). 
Behavioral manifestations can include social anxiety and withdrawal, language and 
learning deficits, hyperactivity, aggression, and self-injurious behaviors. Physical features 
include a large head, prominent forehead and chin, prominent ears, and connective tissue 
findings such as joint laxity, and macroorchidism (Hagerman & Hagerman, 2002; 
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Reviewed by Saul & Tarleton, 2012). Due to skewed X-inactivation, females can show 
some of the same clinical phenotypes observed in full mutation males, although much 
milder; however, this can vary. 
FMR1 alleles undergo a phenomenon known as anticipation, meaning that the signs 
and symptoms of the genetic condition tend to be more severe and/or appear at an earlier 
age as the disorder is passed from one generation to the next (NCI Dictionary). In FXS, the 
maternally inherited allele is at increased risk for expansion from one generation to the 
next, and this risk of expansion correlates with the size of the allele (Fu et al., 1991). The 
risk of a premutation allele expanding to a full mutation is >98% for alleles with >100 
CGG repeats (Nolin et al., 2011). Gray zone allele analysis has shown that about 14% of 
intermediate alleles inherited from the mother are unstable and may expand to the 
premutation range, but not to the full mutation (Nolin et al., 2011). These numbers are still 
being researched, but it is important to consider is that many individuals are carriers of the 
gray zone or premutation allele and do not know until they have children that are affected 
with one of the associated clinical conditions. 
1.1 FRAGILE X PREMUTATION 
The fragile X premutation is defined as having between 55-200 CGG repeats on 
the FMR1 gene (Tassone, Hagerman, & Hagerman, 2014). Individuals with the FMR1 
premutation allele can experience a wide variety of clinical features, and the literature 
shows that about 1/291 females and 1/855 males have the FMR1 premutation (Hunter et 
al., 2014). Historically, individuals with the FMR1 premutation were not found to be at 
increased risk for any clinical phenotypes themselves, but rather were advised of the allele 
expansion risk for their children and grandchildren (Wheeler et al., 2014). Research over 
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the last twenty years has disproved that initial theory and now, the two widely known 
associations for individuals with the FMR1 premutation are fragile X-associated primary 
ovarian insufficiency (FXPOI) and fragile X-associated tremor/ataxia syndrome (FXTAS). 
More recent literature shows that, compared to the general population, individuals with the 
FMR1 premutation are also at increased risk for immune-mediated disorders, fibromyalgia, 
hypertension, and migraines (Wheeler et al., 2014). Although the aforementioned 
symptoms are clinically linked to FXS, the main focus for this study will be to assess 
knowledge of the widely known FXPOI and FXTAS, and more recently, the psychiatric 
manifestations such as depression and anxiety that may be correlated with having the 
FMR1 premutation (Bourgeois et al., 2011; Hagerman & Hagerman, 2013; López-Mourelo 
et al., 2017).  
1.2 FRAGILE X-ASSOCIATED PRIMARY OVARIAN INSUFFICIENCY (FXPOI) 
Primary ovarian insufficiency is defined as the loss of ovarian hormonal function 
at or before the age of 40 and is associated with early onset of menopause (as reviewed by 
Barasoain et al., 2016), and research shows that approximately 16%-20% of females with 
the FMR1 premutation show FXPOI (Rodriguez-Revenga et al., 2009; Schwartz et al., 
1994;). Menopause is associated with the cessation of menses, and research has shown that 
individuals with the FMR1 premutation undergo menopause five years earlier than their 
counterparts without the premutation at approximately age 40 (Murray et al., 2014), but 
the mean age for menopause is 51 years old and ranges between 48 and 54 years (as 
reviewed by Barasoain et al., 2016).  
Features of FXPOI include diminished ovarian reserve leading to irregular menses, 
elevated FSH levels, and reduced fertility (Barasoain et al., 2016). It is important to note 
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that the size of the premutation as well as the percentage of active X chromosomes with 
the mutation has no significant effect on the age at which menopause occurs, and that there 
is no increased risk for POI in females who have the full mutation (Murray, Ennis, 
MacSwiney, Webb, & Morton, 2000). Although about 1/5 women display the POI 
phenotype, it is important for all females with the FMR1 premutation to be aware of these 
risks so that appropriate reproductive options and management can be considered. 
1.3 FRAGILE X-ASSOCIATED TREMOR/ATAXIA SYNDROME (FXTAS) 
Ten years after the discovery of the FMR1 gene, FXTAS was first described in 
2001 in males with the premutation allele (Hagerman et al., 2001). Research shows that 
amongst individuals with the FMR1 premutation, approximately 45% of males and 
between 8%-16% of females are affected with FXTAS (Espinel, Charen, Huddleston, 
Visootak, & Sherman, 2016; Rodriguez-Revenga et al., 2009). In comparison to the early 
onset of POI in premutation females, FXTAS typically onsets in the sixth decade of life 
and older males are at higher risk (Jacquemont et al., 2004). FXTAS is a neurodegenerative 
disorder, which is characterized by progressive cerebellar ataxia, with the major two 
clinical signs being intention tremor or gait ataxia (as reviewed by Saul & Tarleton, 2012). 
Other features include Parkinsonism, autonomic dysfunction and cognitive decline 
(Connon & Larner, 2017; Hagerman et al., 2001; Juncos et al., 2011). Individuals may also 
have differences in mood, such as irritability and/or anger, or psychiatric changes such as 
depression and/or anxiety (Bacalman et al., 2006; Jacquemont et al., 2004). Additionally, 
research has shown that men with the FMR1 premutation and FXTAS may experience 
neuropsychiatric symptoms such as somatization, obsessive compulsive, depression, 
anxiety, psychoticism, agitation/aggression, apathy/indifference, irritability, and nighttime 
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behavioral problems (Grigsby et al., 2016). However, these results showed that these 
psychiatric manifestations may be due to the knowledge of “cognitive and physical 
dysfunction rather than reflecting psychosis” (Grigsby et al., 2016), and there was no 
significant increase in psychiatric manifestations in men with the FMR1 premutation 
without FXTAS.  
FXTAS may present in childhood with seizures or early menopause (Noto, Harrity, 
Walsh, & Marron, 2016). Some medical problems that are related to FXTAS but occur 
before its onset include immune-mediated disorders, hypertension, autonomic dysfunction, 
sleep apnea, hearing loss, and migraines (as reviewed by Hagerman & Hagerman, 2013), 
and these are more common in women with FXTAS (Coffey et al., 2008; Hagerman & 
Hagerman, 2013; Wheeler et al., 2014). The incomplete penetrance of FXTAS in 
individuals with the FMR1 premutation has been suggested to be due to the presence of 
other genetic and/or environmental factors that contribute to its manifestation (Hagerman 
& Hagerman, 2013). 
1.4 FRAGILE X-ASSOCIATED PSYCHIATRIC MANIFESTATIONS 
While having the FMR1 premutation allele increases one’s risk for FXTAS in 
primarily males and FXPOI in females (Cronister et al., 1991; Hagerman et al., 2001), 
recently there has been research that may show that individuals with the FMR1 premutation 
are at increased risk for developing psychiatric disorders such as anxiety and depression. 
Bourgeois et al. (2009) reported clinical manifestations of psychiatric illness in individuals 
with the premutation, including cognitive, mood, anxiety, and other psychiatric disorders 
(e.g. depression and social disorders like schizotypal personality disorder, avoidant 
personality disorder, and social phobia) (Bourgeois et al., 2009). A 2011 study of 85 men 
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and women with the fragile X premutation indicated that the lifetime rates of social phobia 
in individuals with the premutation and without FXTAS were significantly higher than 
controls (Bourgeois et al., 2011). More recently, research has shown an association 
between females with the FMR1 premutation and psychiatric manifestations as well, 
particularly social anxiety disorder (SAD) and autism spectrum disorder (ASD), (López-
Mourelo et al., 2017), with 40% of individuals with a premutation exhibiting depression 
and/or anxiety (Hagerman & Hagerman, 2013). While individuals with FXTAS are more 
likely to show behavioral features including depression and/or anxiety, individuals with 
the premutation without FXTAS are also at risk to show the phenotype, with premutation 
females being more susceptible to social phobia than premutation males (López-Mourelo 
et al., 2017). Additionally, an amalgamation of previous research shows that females with 
the FMR1 premutation appear to be at increased risk for dementia, hypothyroidism, 
hypertension, seizures, fibromyalgia, autoimmune diseases, neuropathies, migraines, and 
postpartum depression (Coffey et al., 2008; Finucane et al., 2012; Hoyos & Thakur, 2017; 
Wheeler et al., 2014).  
Some studies have shown that the development of anxiety disorders in premutation 
females could be associated with the complications involved with FXPOI, the burden of 
taking care of a child with intellectual disabilities (for women who have a child affected 
with FXS), as well as skewed X-inactivation, which could lead to a more apparent FXS 
phenotype in women (Kenna et al., 2013; Mailick et al., 2014; Roberts et al., 2016). 
However, a recent study showed that there is a significant increase in psychiatric 
manifestations in females with the FMR1 premutation, including those who do not have 
children affected with FXS, than in controls. In this same study including 24 women with 
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the premutation and 26 women without it, women with the FMR1 premutation were shown 
to have significantly higher rates of social phobia (42.3%) compared to controls (12.5%) 
(Gossett et al., 2016). 
Although the potential association between being a female with the FMR1 
premutation and increased susceptibility to psychiatric conditions has been established 
since at least the year 2009, the practice guidelines proposed by the National Society of 
Genetic Counselors (NSGC) does not include counseling for these clinical manifestations 
due to the fact that these associations do not yet have enough supportive evidence to 
warrant a change in the clinical guidelines (Finucane et al., 2012).  The NSGC uses a 
stringent evidence-based grading scale to evaluate clinical and research evidence to 
determine whether there is a significant enough association to be included in a practice 
guideline (Practice Guidelines Committee, 2016); therefore, this research is exploratory in 
nature. However, with increasing numbers of patients exhibiting these signs and symptoms, 
it would be beneficial to know what information, if any, patients are learning about the 
psychiatric manifestations, and from which sources. 
1.5 FRAGILE X GRAY ZONE – WHAT WE KNOW 
The American College of Medical Genetics (ACMG) defines the intermediate/gray 
zone as being between 41-54 CGG repeats, but the ACMG laboratory practice committee 
defines this range as being between 45-54 repeats (Kronquist, Sherman, & Spector, 2008; 
Maddalena et al., 2001; Monoghan, Lyon, Spector, & American College of Medical 
Genetics and Genomics, 2013). Additionally, some studies put this number between 40-54 
CGG repeats (Tassone et al., 2012). Other sources report the lower range as low as 34 CGG 
repeats and the higher range at 60 repeats (Hall, 2014; Tassone et al., 2012). The 
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discrepancy between different laboratories and professional societies exists due to the lack 
of knowledge about this allele, and Hall summarizes that, “it is not clear if the gray zone 
should be defined based on the likelihood of expansion in later generations, by associated 
phenotypes, or by underlying molecular abnormalities” (Hall et al., 2014). Additionally, 
there is even discrepancy regarding the naming of this range. These include “gray zone,” 
“intermediate,” “inconclusive,” and “borderline” (Monoghan, Lyon, Spector, & American 
College of Medical Genetics and Genomics, 2013). These inconsistencies themselves make 
it difficult to make clinical assertions and require more study. 
Contrary to the traditional assertion that intermediate allele carriers show no clinical 
manifestations, the clinical spectrum FXS may have recently expanded to include gray 
zone/intermediate allele carriers. It is believed that the incidence of the intermediate/gray 
zone allele in the general population ranges from 0.3%-2.6%, (As reviewed by Hall, 
Tassone, Kepitskaya, & Leehey, 2012) and historically, this was thought to have no 
implications for the individuals themselves, but rather for subsequent generations. 
However, recent research shows that these individuals may have some clinical 
manifestations as well, including Parkinsonism features (defined as having two of the 
following: bradykinesia, resting tremor, rigidity, asymmetric onset), which potentially 
expands the phenotypic spectrum of FXS (Debrey et al., 2016; Hall, Tassone, Kepitskaya, 
& Leehey, 2012; Liu, Winarni, Zhang, Tassone, & Hagerman, 2013).  
The association of intermediate alleles to the manifestation of primary ovarian 
insufficiency is currently being disputed, with some authors finding a higher significance 
of POI in intermediate carriers and others finding no such correlation. In one study of 53 
women with primary ovarian insufficiency, 15/106 alleles (14.2%) were between and 
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including 35 and 53 CGG repeats in the FMR1 gene, compared to 6.5% prevalence in 322 
control alleles of individuals in the general population (Bretherick, Fluker, & Robinson, 
2005). Another study showed 9/190 individuals (4.7%) had POI, although the repeat sizes 
ranged from 41-58 CGG repeats (Bodega et al., 2006), and it is important to take into 
consideration that the upper end of this range falls into the widely described premutation 
zone (anything over 55 CGG repeats). Pastore and colleagues studied women with a 
diminished ovarian reserve and found that out of 62 women, 14.5% had between 35-44 
CGG repeats in the FMR1 gene, considering that since these results may be 
overrepresented in this population of women, it is a potential limitation of this study 
(Pastore et al., 2012). However, recent research completed within the last decade does not 
support these findings. A study of 366 women with POI showed no significant difference 
between intermediates and controls, and these findings were replicated by others using 
similar group sizes (Bennett, Conway, Macpherson, Jacobs, & Murray, 2010; Murray et 
al., 2014; Voorhuis et al., 2012). Due to the conflicting evidence regarding this association, 
this present study will not focus on POI in these individuals. 
In contrast to the conflicting evidence for the association of intermediate alleles 
with POI, it is widely supported that the FXTAS phenotype has been identified in both 
male and female intermediate allele carriers (Hall, Tassone, Kepitskaya, & Leehey, 2012; 
Liu, Winarni, Zhang, Tassone, & Hagerman, 2013), In these studies, five gray zone 
individuals were described to have clinical features consistent with a diagnosis of FXTAS. 
Three of these five individuals were women whose neurological features began in their 50s 
and 60s and slowly progressed over the course of twenty to thirty years. Of these five 
individuals, the smallest CGG repeat size was 47 repeats, which is on the lower end of the 
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gray zone range. A study in 2011 showed that the FMR1 intermediate allele was associated 
with Parkinson disease features in women (Hall et al., 2011). These findings were 
supported by a case study done in 2016 that showed that gray zone carriers exhibited 
Parkinsonism features such as movement disorders and memory loss (Debrey et al., 2016). 
Additionally, a study in Iran involving 154 males with Parkinson’s disease and 190 age-
matched healthy controls showed that 11/154 males (7.14%) with Parkinson’s disease were 
found to be carriers of the FMR1 intermediate allele while 3/190 healthy males (1.57%) 
were found to be intermediate allele carriers (Entezari, Khaniani, Bahrami, Derakhshan, & 
Darvish, 2017). While this knowledge does not yet have clinical utility or guidelines 
indicating whether there is a need to counsel patients about this association, identifying 
more intermediate allele carriers and observing their clinical phenotypes on a grander scale 
may help to expand knowledge about the phenotypic spectrum of FXS. 
1.6 AVAILABLE RESOURCES 
Many online community support resources exist for individuals with FXS as well 
as for individuals with the FMR1 premutation. A quick Facebook search reveals a number 
of groups for individuals with FXS and those who have the premutation, each of which has 
between a few hundred and a few thousand members, creating a supportive community 
worldwide. However, it is difficult to find these groups for individuals who are carriers of 
the intermediate/gray zone allele. Espinel et al. (2016) found that having “family members 
[familiar with FXS], national and community organizations, research studies, 
compassionate physicians, and interactions with other individuals with the FMR1 
premutation” facilitated patients’ own healthcare journeys (Espinel, Charen, Huddleston, 
Visootak, & Sherman, 2016). However, barriers included lack of knowledge about FXS 
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among healthcare providers and among the women themselves, shortage of premutation-
specific support, and targeted educational materials (Espinel, Charen, Huddleston, 
Visootak, & Sherman, 2016). In this day and age where social media has the potential to 
be a significant source of support at one’s fingertips, it is important to learn which groups, 
if any, are most helpful so genetic counselors may direct their patients there.  
A recently published paper by Rocha et al. (2017) showed that individuals are 
turning to social media (e.g. blogs, Facebook groups, and Twitter) to find and connect with 
other individuals who are on the same healthcare journeys. Out of 103 individuals who 
participated in the research, Facebook was the most popular source for support, with 99% 
of them turning to this medium as a resource (Rocha et al., 2017). Results showed that 
social media was used to “look for information about their diagnosis or test results (83%), 
read posts from rare disease groups or organizations (73%), participate in conversations 
about their diagnosis (67%), and connect with others to find support (58%)” (Rocha et al., 
2017). Anecdotal findings of the researcher herself found that mothers of children with 
FXS often posted about their children’s trials and tribulations, as well as their 
achievements, to others experiencing the same struggles and accomplishments. They 
sought out tips on how to have their child sit still for haircuts, asked for recommendations 
for doctors, and how best to potty-train their children with FXS among other questions that 
could be answered by others on the same journey. Additionally, individuals asked about 
guidance regarding their genetic testing results (FXS groups), hope for successful 
pregnancy based on hormone levels and various reproductive therapies (POI groups) as 
well as for support regarding declining health (FXTAS groups). These online groups serve 
as support for parents all over the world and allow them to feel as if they are not alone in 
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navigating their child’s health and well-being. Having a better idea of which of these 
groups (and other resources) offer the most support is beneficial to genetic counselors and 
other healthcare providers alike. 
1.7 RATIONALE FOR RESEARCH 
Currently, the ACMG recommends carrier screening for FXS to women with a 
family history of intellectual disability and/or autism, those who are known to have the 
FMR1 premutation, as well as those with a family history of FXS (Sherman, Pletcher, & 
Driscoll, 2005). ACMG does not recommend population carrier screening for FXS. The 
American College of Obstetricians and Gynecologists (ACOG) published a committee 
opinion echoing the recommendations of the ACMG but adding that women who have 
unexplained ovarian insufficiency or failure or an elevated follicle-stimulating hormone 
level before age 40 years should also get FMR1 carrier screening (American College of 
Obstetricians and Gynecologists Committee on Genetics, 2010). They also recommend 
offering testing and genetic counseling to women who request it, regardless of family 
history. However, with FXS mutation screening being offered on numerous prenatal 
screening panels, there is an increase in the uptake of FMR1 carrier testing making it 
important to have accurate information on which to base clinical care as well as with which 
to make an informed decision about whether to pursue screening (Finucane, Lincoln, 
Bailey, & Martin, 2017).  
The literature shows that 1/291 females and 1/855 males have the FMR1 
premutation (Hunter et al., 2014), and having a premutation or intermediate/gray zone 
allele has the potential to induce anxiety in the client. A study done in Australia showed 
that women with no family history of FXS who were found to have the FMR1 premutation 
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did experience anxiety and stress since they were not expecting to receive an abnormal 
result during routine prenatal carrier screening (Beard, Amor, Di Pietro, & Archibald, 
2016). Additionally, few educational materials are available for patients and providers 
regarding the clinical spectrum of FXS (Espinel, Charen, Huddleston, Visootak, & 
Sherman, 2016). Providing appropriate pretest counseling about the risks of carrying one 
of these alleles as well as its implications for not only the client, but also to her children, is 
imperative in providing thorough informed consent. While many people are counseled 
about the risks of developing FXPOI as well as FXTAS, it is not known whether 
individuals with the FMR1 premutation are aware of the potential risks for psychiatric 
manifestations such as depression and anxiety. Of course, this is an area of research that is 
still being developed and more information and data needs to be collected before making 
this clinical assertion or counseling about it. However, shedding light on this issue would 
provide genetic counselors with a better understanding with which to approach informed 
consent and clinical care with their patients.  
Both males and females with the FMR1 premutation are at risk for FXTAS and 
women are at increased risk for FXPOI. Hearing about the risks of these two manifestations 
alone can be life-altering for individuals who are learning of their premutation status, but 
recent research shows that the need to counsel about psychiatric manifestations may be 
necessary. Currently, the guidelines set forth by the NSGC for counseling of FXS involves 
providing information about FXTAS and FXPOI for individuals who are found to have the 
FMR1 premutation, but not for the psychiatric manifestations that are now being observed 
in these individuals (Finucane et al., 2012). Additionally, these guidelines do not include 
any type of counseling for gray zone allele carriers, highlighting the need to study this topic 
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further. Therefore, this study may indicate the need to update the current clinical practice 
guidelines for FXS. 
Initially, individuals in the intermediate allele range were informed that they would 
not show any clinical manifestations. However, a handful of case reports are showing that 
intermediate allele carriers are experiencing Parkinsonism features and FXTAS, which 
brings to attention the importance of identifying more individuals in this gray zone range. 
Although the clinical manifestations of intermediate allele carriers have not yet been 
discussed broadly in a clinical context, the responses ascertained from this study may have 
implications for practice. In light of these recent developments, genetic counselors may 
need to expand their procedures for informed consent when counseling about prenatal 
carrier screening panels to include these recent clinical developments and provide thorough 
pretest counseling. Further elucidating the phenotype in a greater number of individuals 
would help to establish the more common features that are observed and delegate how 
better to counsel individuals who are identified as intermediate allele carriers. Additionally, 
the profession of genetic counseling involves life-long learning and it is important to be 
aware of new research for not only the purposes of continuing education but also the 
resultant improvement in patient-centered counseling. 
A previous thesis project done by a Master’s Student in Genetic Counseling at 
Brandeis University explored individuals with the FMR1 premutation knowledge of the 
associated clinical phenotypes by using survey methodology. The survey included 
awareness of FXPOI and FXTAS but not any of the psychiatric manifestations that may be 
associated with having a premutation allele in FMR1. Additionally, the sample size was 
17 
small (n=43) and it did not include intermediate/gray zone allele carriers (Metterville, 
2009).  
This study aims to expand upon that research by gauging premutation and 
intermediate allele carriers’ knowledge of not only their risks for FXTAS and FXPOI, but 
also the psychiatric symptoms that are now thought to be associated with FXS. Secondly, 
this study seeks to expand knowledge about intermediate allele carriers of the FMR1 gene. 
There exist some case reports of their clinical manifestations, but there needs to be more 
documentation of their clinical features to expand the phenotype of this intermediate/gray 
zone range. Lastly, community support resources for individuals with FXS and those who 
are have the FMR1 premutation are in abundance, but there are no resources easily located 
for intermediate allele carriers. Identifying resources that would be most useful to the 
patients would help to provide genetic counselors with better tools with which to direct 
patients for support, especially since research is showing that psychiatric symptoms may 
be present in individuals with the FMR1 premutation and referral to psychological services 












Table 1.1 Molecular Classification and Clinical Manifestations Based on # of CGG 




# of Repeats Clinical Phenotype 




Potential Parkinsonism and neuropsychiatric 
features (later in life) 
Premutation 55-200 
Fragile X-associated Tremor/Ataxia Syndrome 
(FXTAS), Fragile X-associated Primary 
Ovarian Insufficiency (FXPOI) in females, 
potential for psychiatric manifestations (i.e. 
depression, anxiety) 
Full Mutation >200 







IS CURRENT FRAGILE X SYNDROME COUNSELING ENOUGH? EXPANDING THE 
CLINICAL PHENOTYPE OF FRAGILE X IN PREMUTATION AND INTERMEDIATE 
ALLELE CARRIERS1
                                                          
1 Girnary, Z. S., Klusek, J., McConkie-Rosell, A., Hill-Chapman, C. R. To be submitted to 
Journal of Genetic Counseling. 
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ABSTRACT 
Fragile X syndrome (FXS) is caused by a triplet repeat expansion on the FMR1 
gene. Individuals with >200 repeats have FXS, while individuals between 45-54 and 55-
200 repeats have the FMR1 intermediate allele and premutation, respectively. FXS is 
characterized by autism and intellectual disability while the premutation is associated with 
Fragile X-associated tremor/ataxia syndrome (FXTAS) and Fragile X-associated primary 
ovarian insufficiency (FXPOI). However, recent research shows that the premutation may 
be associated with psychiatric manifestations. Currently, there are no established clinical 
features associated with the intermediate allele. 
This study sought to 1) study knowledge regarding FXTAS, FXPOI, as well as the 
potential for psychiatric manifestations in individuals with the premutation; 2) study which 
features, if any, intermediate allele carriers exhibit, and 3) learn which resources are most 
helpful for FXS. Participants were recruited through online Facebook groups and 
completed one of two surveys. Results showed that 1) individuals in both groups 
overestimated their chances for FXS-related disorders; 2) significantly more individuals 
with the intermediate allele experienced depression/anxiety than expected; and 3) the most 
helpful resources for learning about FXS were internet websites and conversations with 
health providers and other individuals with the FMR1 premutation. These findings reveal 
that genetic counselors should place more emphasis on the genetics of FXS and its 
associated phenotypes to both groups and offer both traditional sources of support as well 
as referral to Facebook groups to facilitate conversations with others in similar situations. 




Fragile X syndrome (FXS), one of the leading causes of X-linked intellectual 
disability and autism, affects between 1/4,000 to 1/7,000 males and between 1/8,000 to 
1/11,000 females, (Cornish, Turk, & Hagerman, 2008; Fu et al., 1991; Hunter et al., 2014; 
Turner, Webb, Wake & Robinson., 1996) and is caused by an expansion of a cytosine-
guanine-guanine (CGG) trinucleotide repeat in the 5’ untranslated region of the Fragile X 
Mental Retardation 1 (FMR1) gene (Verkerk et al., 1991). The clinical phenotype of FXS 
varies depending on the number of CGG repeats observed in an individual, and these are 
summarized in Table 2.1 (Biancalana, Glaeser, McQuaid, & Steinbach, 2015; Debrey et 
al., 2016; Usdin et al., 2014). Males with greater than 200 CGG units have fragile X 
syndrome and females with greater than 200 CGG repeats are considered carriers of the 
full mutation. Any individual who has between 55 and 200 CGG units is considered to 
have the FMR1 premutation and having 45-54 repeats puts an individual in the 
intermediate/gray zone allele range (Sherman, Pletcher, & Driscoll, 2005; Tassone et al., 
2012). Traditionally, having fewer than 45 CGG units leads to no clinical manifestations 
and is considered phenotypically “normal.” 
Males with a full mutation show several clinical features, including moderate 
intellectual disability and autism spectrum disorder (ASD). Behavioral manifestations can 
include social anxiety and withdrawal, language and learning deficits, hyperactivity, 
aggression, and self-injurious behaviors. Physical features include a large head, prominent 
forehead and chin, prominent ears, and connective tissue findings such as joint laxity, and 
macroorchidism (Hagerman & Hagerman, 2002; Reviewed by Saul & Tarleton, 2012). Due 
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to skewed X-inactivation, females can show some of the same clinical phenotypes observed 
in full mutation males, although much milder; however, this can vary. 
Individuals with the FMR1 premutation allele can experience a wide variety of 
clinical features, and the literature shows that about 1/209 females and 1/430 males have 
the FMR1 premutation (As reviewed by Hall, 2014). The two widely known associations 
for the FMR1 premutation are fragile X-associated primary ovarian insufficiency (FXPOI) 
and fragile X-associated tremor/ataxia syndrome (FXTAS). More recent literature shows 
that, compared to the general population, premutation carriers are also at increased risk for 
immune-mediated disorders, fibromyalgia, hypertension, and migraines (Wheeler et al., 
2014). Although the aforementioned symptoms are clinically linked to fragile X syndrome, 
the main focus of this study will be assessing knowledge of the widely known FXPOI and 
FXTAS, and more recently, the psychiatric manifestations such as depression and anxiety 
that may be correlated with having the FMR1 premutation allele (Bourgeois et al., 2011; 
Hagerman & Hagerman, 2013; López-Mourelo et al., 2017).  
While having the FMR1 premutation allele increases one’s risk for fragile X 
tremor/ataxia syndrome (FXTAS) in primarily males (but also females) and fragile X-
associated primary ovarian insufficiency (FXPOI) in females (Cronister et al., 1991; 
Hagerman et al., 2001), recently there has been research that may show that premutation 
carriers are at increased risk for developing psychiatric disorders such as anxiety and 
depression. Bourgeois et al. (2009) reported clinical manifestations of psychiatric illness 
in premutation carriers, including cognitive, mood, anxiety, and other psychiatric 
disorders. While individuals with FXTAS are more likely to show behavioral features 
including depression and/or anxiety, individuals with the premutation without FXTAS are 
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also at risk to show the phenotype, with premutation females being more susceptible to 
social phobia than premutation males (López-Mourelo et al., 2017). Additionally, an 
amalgamation of previous research shows that females with the FMR1 premutation allele 
appear to be at increased risk for dementia, hypothyroidism, hypertension, seizures, 
fibromyalgia, autoimmune diseases, neuropathies, migraines, and postpartum depression 
(Coffey et al., 2008; Finucane et al., 2012; Hoyos & Thakur, 2017; Wheeler et al., 2014).  
Although the potential association between being a female with the FMR1 
premutation and increased susceptibility to psychiatric conditions has been established 
since at least the year 2009, the practice guidelines proposed by the National Society of 
Genetic Counselors (NSGC) does not include counseling for these clinical manifestations 
due to the fact that these associations have not yet been well established (Finucane et al., 
2012).  The NSGC uses a stringent evidence-based grading scale to evaluate clinical and 
research evidence to determine whether there is a significant enough association to be 
included in a practice guideline (Practice Guidelines Committee, 2016); therefore, this 
research is exploratory in nature. However, with increasing numbers of patients exhibiting 
these signs and symptoms, it would be beneficial to know what information, if any, patients 
are learning about the psychiatric manifestations, and from which sources. 
Contrary to the traditional assertion that intermediate allele carriers show no clinical 
manifestations, the clinical spectrum of fragile X syndrome may have recently expanded 
to include gray zone/intermediate allele carriers. The association of intermediate alleles to 
the manifestation of primary ovarian insufficiency is currently being disputed, with some 
authors finding a higher significance of POI in intermediate carriers and others finding no 
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such correlation. Due to the conflicting evidence regarding this association, this study will 
not focus on POI in these individuals. 
In contrast to the conflicting evidence for the association of intermediate alleles 
with POI, recent research has shown that the FXTAS phenotype and some Parkinsonism 
features (Defined as having two of the following: bradykinesia, resting tremor, rigidity, 
asymmetric onset) has been identified in both male and female intermediate allele carriers 
(Hall, Tassone, Kepitskaya, & Leehey, 2012; Liu, Winarni, Zhang, Tassone, & Hagerman, 
2013). While this knowledge does not yet have clinical utility or guidelines indicating 
whether there is a need to counsel about this association, identifying more intermediate 
allele carriers and observing their clinical phenotypes on a grander scale may help to 
expand knowledge about the phenotypic spectrum of FXS. 
Many resources exist for individuals with fragile X syndrome as well as for 
individuals with the FMR1 premutation. However, it is difficult to find these groups for 
individuals who are carriers of the intermediate allele. In this day and age where social 
media has the potential to be a significant source of support at one’s fingertips, it is 
important to learn which groups, if any, are most helpful so genetic counselors and other 
health care providers may direct their patients there. These groups serve as support for 
parents all over the world and allow them to feel as if they are not alone in navigating their 
child’s health and well-being.  
MATERIALS AND METHODS 
2.1 PARTICIPANTS 
Males and females with either the FMR1 premutation or carriers of the FMR1 
intermediate/gray zone allele were invited to participate in this study. Participants had to 
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be over 18 years of age and have a formal diagnosis of having of one of these alleles 
through means of previous genetic testing. Only English-speaking participants were 
included in the study due to limited resources available for interpretation from English to 
other languages. Additionally, an 80% questionnaire completion rate was required for 
inclusion in data analysis. 
Individuals with the FMR1 Intermediate/Gray Zone Allele  
Thirty-nine FMR1 intermediate allele carriers participated in the study, of which 30 
completed 80% of the questionnaire, thus rendering inclusion into data analysis. Of these 
30 participants, 3/30 (10%) were male, 21/30 (70%) were female, and 6/30 (20%) chose 
not to answer. The participants’ ages ranged from 27 to 77 years old. Regarding country of 
residence, 15/30 (50%) lived in the United States and 15/30 (50%) lived abroad (e.g. United 
Kingdom, England, Ireland). Their education levels ranged from less than high school 
(1/30; 0.03%) to graduate or professional degrees (6/30; 20%), of which five had master’s 
degrees and one individual had a medical degree. Overall, 20/30 (67%) of participants had 
some college education or higher (Table 2.2). 
Individuals with the FMR1 Premutation  
Two hundred forty-seven individuals with the FMR1 premutation started the 
questionnaire, out of which 184 participants had 80% completion and subsequent inclusion 
into further analysis. Of those excluded, 12 of them started the survey and said that they 
have a grandson with FXS, but that their own mutation status was unknown. The remaining 
excluded participants marked that they had the premutation but completed none of the other 
items on the questionnaire. Of these participants, 3/184 (1.6%) were male, 124/184 (67.4%) 
were female, and 57/184 (31%) chose not to answer. Their ages ranged from 26 to 69 years 
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old. Regarding country of residence, 66/184 (35.9%) live in the United States and 62/184 
(33.7%) live abroad (e.g. Australia, Belgium, Canada, England, France, Harris, India, 
Ireland, Netherlands, New Zealand, Qatar, Scotland, South Africa, Spain, Switzerland, and 
Wales). Their education levels ranged from less than high school (2/184; 1.1%) to graduate 
or professional degrees (57/184; 31%), of which 13 held Bachelor’s degrees, 29 had 
Master’s degrees, two had doctoral degrees, three held law degrees, and four held medical 
degrees. Interestingly, one of the participants had a master’s degree in Genetic Counseling. 
Overall, 114/184 (62%) of participants had some college education or higher (Table 2.2).  
2.3 INSTRUMENTATION 
For purposes of recruitment, an announcement (See Appendix A) was created to be 
posted onto various social media sites. Along with this, an online questionnaire that was 
programmed using skip logic was developed through SurveyMonkey.com. Interested 
participants were asked to complete one of two web-based questionnaires – one for 
individuals with the FMR1 premutation and another for intermediate/gray zone allele 
carriers (See Appendices B and C, respectively). Use of an online survey kept participant 
answers anonymous, and no identifying information was collected from the questionnaire. 
All data was stored on a password protected website (SurveyMonkey.com) as well as a 
password protected computer. Additionally, a debriefing form was included at the end of 
the survey due to the fact that some questions may be perceived as personal and/or 
sensitive, and a list of both domestic and international psychological support resources was 
included (Appendix D). 
Data was collected using survey methodology and responses were measured using 
two similar, but separate questionnaires. These measures were modified from an 
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unpublished thesis done by a student at Brandeis University in 2009 (Metterville, 2009). 
The original questions were altered to fit the needs of this study to reflect the type of data 
that this study sought to collect (e.g. some of the questions using “yes, no, or unsure” as 
answer choices were changed instead to a Likert scale evaluating percentage of risk, and a 
separate section was created to evaluate the potential psychiatric manifestations associated 
with FXS).  
Both questionnaires contained the same six demographic questions as well as the 
same questions regarding general knowledge about FXS. Quantitative questions were 
asked to assess categorical information about the participants, such as gender, age, country 
of residence, and education level of the participants. Each questionnaire also contained 
questions regarding the year and reason for fragile X testing, which individual in the family 
(if anyone) has FXS, what they were told about their result and implications, and the 
resource where the most useful information about FXS was obtained. Only the premutation 
questionnaire contained questions specific to fragile X-associated tremor/ataxia syndrome 
(FXTAS), fragile X-associated primary ovarian insufficiency (FXPOI), and the newly 
developed questions regarding the potential psychiatric manifestations that may be 
associated with FXS. The questions for gray zone carriers were created in a similar format 
to the existing survey questions being used for individuals with the FMR1 premutation but 
instead asked open-ended questions assessing which, if any, symptoms these patients were 
experiencing, whether they would benefit from an online support group, and whether his 
or her result has affected reproductive decision-making. Both questionnaires contained a 
mix of open and closed ended questions which included multiple choice questions, select 
all that apply, and evaluation of percentage of risk using a Likert scale. 
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2.2 PROCEDURES 
Recruitment for this study occurred from September 1, 2017 to January 20, 2018 
using Dillman’s Internet Survey Design (Dillman, Smyth, & Christian, 2014). Recruitment 
notices were made weekly in September, biweekly in October, and once a month in 
November, December, and January. An announcement (Appendix A) about the research 
study was posted on Facebook on various fragile X syndrome (FXS) support groups, which 
provided a brief introduction, invitation, and link to the questionnaire on 
SurveyMonkey.com. Permission was obtained from representatives of each group prior to 
posting of the announcement. The various Facebook support groups in which the notice 
was posted included the following: Fragile X syndrome, Girls with Fragile X syndrome, 
Fragile X Female Carrier Symptoms, Fragile X Society, Fragile X, Fragile X Society – 
India, Fantastically Fragile X – The FX Brag Room, as well as the Facebook groups of 
both local and international fragile X foundations including but not limited to, the FRAXA 
Research Foundation, Fragile X Research Foundation of Canada, the Facebook group of 
the Fragile X support group in the Netherlands, “Fragiele x vereniging Nederland”, 
Premature Ovarian Failure - Primary Ovarian Insufficiency, and the National Ataxia 
Foundation.  
The invitation described the study to participants, provided the investigators’ 
contact information, and allowed participants to access the study. Potential participants 
were then able to decide whether they wanted to continue with the questionnaire, which 
was estimated to take about 20 minutes to complete. Consent was assumed upon clicking 
“I agree” on the introductory page of the survey and subsequent survey completion. 
Participation in this study was voluntary; participants were not compensated to participate 
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and had the option to withdraw from the study at any time. Participants were given the 
option to include their email address to be contacted once study results were ready. Since 
demographic information was collected at the end of the survey, failure to complete the 
demographic section resulted in exclusion from data analysis.  
2.4 DATA ANALYSIS 
The methodology for this study was quantitative and qualitative. 
SurveyMonkey.com software was used to collect the data, and data collection was 
completed by the end of January 2018. Data was analyzed in February 2018, where 
quantitative analysis was done on the questionnaire items, and thematic analysis methods 
grounded in theory were utilized to identify themes within open-ended responses. 
Demographic information was used to determine descriptive statistics for each category 
within each population and frequencies were calculated for the items on the questionnaire 
regarding knowledge about FXS and its associated phenotypes. An analysis using 
G*Power predicted that a minimum of 28 participants in each group (i.e., individuals with 
the FMR1 premutation and intermediate allele/gray zone carriers) would be needed in order 
to detect statistically significant differences at α=.05, power (1 - β) of .95, and an effect 
size of .50.   
RESULTS 
2.5 FMR1 GRAY ZONE  
Testing for and Counseling about FXS 
Of 30 total participants or individuals with the intermediate allele, 12/30 (40%) said 
that they underwent FXS testing because they have a child or multiple children with FXS, 
3/30 (10%) had a family history of FXS, 2/30 (6.67%) have a family member with the 
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FMR1 premutation, 5/30 (16.7%) did it as part of prenatal carrier screening, 6/30 (20%) 
said “other,” and 2/30 (6.7%) were unsure about their reasons for testing (Figure 2.1). Of 
those who stated “other,” one of the individuals had testing because she herself had POF, 
one individual was researching FXS and noticed the pattern of FXS in her family to which 
her geneticist agreed to testing her, one of the individuals was responding on behalf of his 
or her son who is a carrier of the intermediate/gray zone allele, two individuals had children 
with ASD which then spurred their own testing, and one individual was diagnosed via an 
amniocentesis that his or her mother had which revealed a finding in the gray zone range 
in the patient.  
Many of the participants had family members diagnosed with FXS, and most of 
these individuals had multiple affected family members. Of the thirty individuals with the 
FMR1 intermediate/gray zone allele, 14/30 (46.7%) of individuals said that they had son(s) 
with FXS, 7/30 (23.3%) had affected daughters, 2/30 (6.7%) had affected brothers, 1/30 
(3.3%) had an affected sister, 1/30 (3.3%) said that his or her grandsons were affected, 1/30 
(3.3%) had an affected cousin, and 1/30 (3.3%) had an affected wife. Of the participants, 
5/30 (16.7%) had no one in his or her family affected with FXS, and 3/30 (10%) of 
individuals stated that they had other family members with the FMR1 premutation. 
Regarding when the participants were diagnosed with being an intermediate/gray 
zone allele carrier, 26/30 (86.7%) were diagnosed between 1991-2017, 1/30 (3.3%) was 
diagnosed before 1991, and 3/30 (10%) were unsure (Figure 2.1). Of those that were 
diagnosed between 1991-2017, 11/26 (42.3%) were diagnosed within the last five years. 
At the time that these individuals were found to be intermediate/gray zone allele carriers, 
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24/30 (80%) stated that they had received genetic counseling, 3/30 (10%) said that they 
had not, and 3/30 (10%) were unsure (Figure 2.1).  
Of the participants, 17/30 (56.7%) individuals had a formal discussion about FXS 
with their healthcare provider between 1991-2017, 1/30 (3.3%) had a discussion before 
1990, 4/30 (13.3%) were unsure, and 8/30 (26.7%) said that they have never had a formal 
discussion about FXS with their healthcare provider (Figure 2.1). Of those that had a formal 
discussion between 1991-2017, 7/17 (41.2%) had it within the last five years. Of the 
discussions and of the information received, 7/30 (23.3%) were told that there were no 
implications for their own health 3/30 (10%) of individuals were referred to someone else 
(either a genetic counselor or another healthcare provider), 5/30 (16.7%) received “very 
little” or no information, and 1/30 (3.3%) did not remember. Regarding the information 
that they received, 1/30 (3.3%) individual said that he/she was told that her baby “could be 
mentally retarded,” 3/30 (10%) of individuals said that it “may be associated with POF” 
and/or “early menopause,” of which one of those individuals did in fact have POF, and 
4/30 (13.3%) said that their result “may have an impact on [his or her] grandchildren” 
and/or “[his or her] grandchildren may have full-blown FXS.” Of the participants, 1/30 
(3.3%) participant said that he or she was told to “inform [his or her] daughter.” 
Knowledge and Education about FXS 
There were two general knowledge questions about FXS presented to both groups, 
and these results can be found in Figures 2.2 and 2.3. Pertaining answers to the question, 
“Who has the greatest chance of inheriting a fragile X premutation,” only 7/30 (23.3%) 
FMR1 intermediate/gray zone allele carriers answered the question correctly (Figure 2.3A), 
with the answer being “Daughter of a male premutation carrier.” Of the FMR1 
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intermediate/gray zone allele carriers, 8/30 (26.7%) of individuals responded, “son of a 
female premutation carrier,” 3/30 (10%) responded “daughter of a female premutation 
carrier, 5/30 (16.7%) of individuals stated that they “all have the same chance,” and 7/30 
(23.3%) stated that they were either unsure or did not answer the question (Figure 2.2). 
Regarding the question, “Who has the greatest chance of having a child with fragile X 
syndrome,” 13/30 (43.3%) individuals answered the question correctly (Figure 2.3B), the 
answer being “female premutation carrier.” 2/30 (6.7%) individuals responded “male 
premutation carrier, 6/30 (20%) said “both [males and females with the FMR1 premutation] 
have the same chance of having a child with FXS,” and 9/30 (30%) of individuals were 
either unsure or did not answer the question (Figure 2.2).  
We surveyed participants’ knowledge about the chances of an individual with the 
FMR1 intermediate/gray zone allele developing conditions seen in FXS as well as in the 
general population, with the pre-existing knowledge that there are no true established 
clinical features associated with carrying the FMR1 intermediate/gray zone allele. The 
chances of developing these conditions were evaluated using a Likert scale, and 
participants were asked about conditions related to FXS as well as those that are not. 
Conditions unrelated to FXS and its associated phenotypes included things like heart 
disease, kidney problems, uterine fibroids, diabetes, gastric reflux, and glaucoma. 
Conditions related to or potentially associated with FXS and its associated phenotypes 
included early menopause, social anxiety, depression, and tremor/ataxia. Of 30 total 
participants, 17-22 individuals answered these questions, and results will be based on this 
subgroup. These findings are summarized in Figure 2.4. Results showed that for every 
condition, there was at least one person who stated that there was a 0% chance of 
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developing the phenotype. Additionally, at least one individual stated that the maximum 
chance for developing each condition was 50% or higher, with the maximum numbers 
being 75% chance of developing early menopause, 81% chance of developing gastric 
reflux, 85% chance for tremor/ataxia, 90% chance of developing social anxiety, and a 90% 
chance for depression. The mean responses for the chance of developing the following 
conditions which are unrelated to FXS or its associated phenotypes were as follows: heart 
disease (15.8%), kidney problems (14.6%), uterine fibroids (21.3%), diabetes (18.4%), 
gastric reflux (27.8%), and glaucoma (18.9%). The mean responses for the chance of 
developing the following conditions which are related to FXS or thought to be related to 
FXS or its associated phenotypes were as follows: early menopause (44%), social anxiety 
(48%), depression (46.1%), and tremor/ataxia (37.5%). These results indicate that 
individuals did state that there was a higher chance of developing conditions which are 
related to FXS and its associated phenotypes than those that are not. 
FXS and Reproductive Decision-Making  
The results regarding the impact of the diagnosis on reproductive decision-making 
can be found in Figure 2.5A. Of the participants, 13/30 (43.3%) of participants said that 
his or her result did not affect their reproductive decisions. However, 4/30 (13.3%) of 
participants said that his or her FMR1 result led to the use of reproductive technologies, 
8/30 (26.7%) stated that they chose to not have more children, and 5/30 (16.7%) did not 
answer the question. 
Personal Clinical Experiences 
We surveyed whether individuals with the intermediate/gray zone allele 
experienced any symptoms themselves, and results can be found in Figure 2.6. Of the 
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individuals with the FMR1 intermediate/gray zone allele, 4/30 (13.3%) have tremors, 1/30 
(3.3%) has ataxia, 1/30 (3.3%) has gait abnormalities, 3/30 (10%) have neuropathy, 0/30 
(0%) have experienced Parkinsonism features (Defined as having two of the following: 
bradykinesia, resting tremor, rigidity, asymmetric onset), 6/30 (20%) have experienced 
memory loss, 18/30 (60%) have anxiety, and 14/30 (46.7%) have depression. Additionally, 
only 2/30 (6.7%) of individuals said that there is someone in his or her family who has a 
formal diagnosis of Parkinson disease, and these individuals included a grandfather and a 
great-grandfather. 
Utilization of Support  
Of the individuals with the FMR1 intermediate/gray zone allele, 24/30 (80%) 
individuals stated that they would be “likely” or “very likely” to access an online support 
group for FMR1 intermediate/gray zone allele carriers (Figure 2.7). Of the participants, 
11/30 (36.7%) of participants stated that they would use a support group to “not feel alone” 
and to be able to “compare stories,” with one individual stating: 
I feel like having children with fragile X is a lonely place to be and having people 
to compare stories to or for advice and somebody to understand where you’re 
coming from is something that would carry a high value. 
Of the participants, 5/30 (16.7%) of individuals stated that they would use a support group 
to ask questions, 5/30 (16.7%) would use it to give information, and 5/30 (16.7%) said that 
they would use it to ask for advice. 3/30 (10%) of individuals listed that a support group 




2.6 FMR1 PREMUTATION 
Testing for and Counseling about FXS  
Of 184 total participants with the FMR1 premutation, 107/184 (58.2%) said that 
they underwent FXS testing because they have a child or multiple children with FXS, 
24/184 (13%) had a family history of FXS, 17/184 (9.2%) have a family member with the 
FMR1 premutation, 22/184 (12%) did it as part of prenatal carrier screening, 9/184 (2.7%) 
said “other,” and 5/184 (2.7%) replied that they had never been tested (Figure 2.1). Of 
those who stated “other,” many of those individuals had FXS testing as part of their 
infertility/POF work-up, and one individual had it done for displaying Parkinsonism 
features.  
Many of the participants had family members who have been diagnosed with FXS, 
and similarly to the pattern that was seen in the intermediate/gray zone allele carriers, many 
of these individuals (65/184 or 35.3%) had more than one family member diagnosed with 
FXS in their family. Of these 184 individuals with the FMR1 premutation, 106/184 (57.6%) 
of individuals stated that they had a child or multiple children with FXS, 15/184 (8.2%) 
had affected siblings, 26/184 (14.1%) had nieces or nephews with FXS, 8/184 (4.3%) had 
affected cousins, 11/184 (6.0%) had affected grandchildren, 3/184 (1.6%) had affected 
parents, 15/184 (8.2%) had distant relatives with FXS, and 17/184 (9.2%) had no one in 
his or her family diagnosed with FXS. 
Regarding when the participants were diagnosed with having the FMR1 
premutation, 171/184 (92.9%) were diagnosed between 1991-2017, 11/184 (6%) were 
diagnosed before 1991, and 2/184 (1.1%) were unsure (Figure 2.1). Of those that were 
diagnosed between 1991-2017, 79/171 (46.2%) were diagnosed within the last five years. 
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At the time that these individuals were found to have the FMR1 premutation, 116/184 
(63%) stated that they had received genetic counseling, 60/184 (32.6%) said that they had 
not, and 8/184 (4.3%) were unsure (Figure 2.1).  
Of the participants with the FMR1 premutation, 128/184 (69.6%) individuals had a 
formal discussion about FXS with their healthcare provider between 1991-2017, 3/184 
(1.6%) individuals had a discussion before 1990, 9/184 (4.9%) were unsure, and 44/184 
(23.9%) said that they have never had a formal discussion about FXS with their healthcare 
provider (Figure 2.1). Of those that had a formal discussion between 1991-2017, 84/128 
(65.6%) had it within the last five years. Out of the individuals with the FMR1 premutation, 
one hundred forty-nine individuals gave additional detail into what information was 
received from his or her healthcare provider. Of the discussions that were had and 
information that was received, 59/149 (39.6% received “very little” or no information, 
45/149 (32.9%) were counseled about FXTAS and FXPOI, 22/149 (14.8%) received 
information about reproductive options/chance of having a child with FXS, 20/149 (13.4%) 
were referred to someone else, either a genetic counselor or another specialist, and 8/149 
(5.4%) received resources or a print-out. Interestingly, 2/149 (1.3%) of individuals were 
informed about anxiety and depression, 2/149 (1.43%) of participants were told that they 
“were not affected” and only 1/149 (0.5%) individual stated that he/she was told to inform 
family members to facilitate their testing. One individual quoted that he or she was told 
“this [result] most certainly could not affect my mental health.” 
Knowledge and Education about FXS 
There were two general knowledge questions about FXS that were presented to 
both groups and results can be seen in Figures 2.2 and 2.3. Pertaining answers to the 
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question, “Who has the greatest chance of inheriting a fragile X premutation,” 93/184 
(50.5%) of individuals with the FMR1 premutation answered the question correctly (Figure 
2.3C), with the answer being “Daughter of a male premutation carrier.” Of the individuals 
with the FMR1 premutation, 34/184 (18.5%) of individuals responded, “son of a female 
premutation carrier,” 13/184 (7.1%) responded “daughter of a female premutation carrier, 
31/184 (16.8%) of individuals stated that they “all have the same chance,” and 9/184 
(4.9%) stated that they were unsure (Figure 2.2). Regarding the question, “Who has the 
greatest chance of having a child with fragile X syndrome,” 117/184 (63.6%) individuals 
with the FMR1 premutation answered the question correctly (Figure 2.3D), the answer 
being “female premutation carrier.” Of these participants, 5/184 (2.7%) responded “male 
premutation carrier, 52/184 (28.3%) said “both [males and females with the FMR1 
premutation] have the same chance of having a child with FXS,” and 10/184 (5.4%) 
participants were either unsure (Figure 2.2).  
We surveyed participants’ knowledge about the chances of an individual with the 
FMR1 premutation developing conditions seen in FXS as well as in the general population. 
The chances of developing these conditions were evaluated using a Likert scale (0% – 
100%), and participants were asked about conditions that are related to FXS as well as 
those that are not. Questions were phrased as such: “What is the likelihood [0% – 100%] 
of a fragile X [premutation or intermediate/gray zone allele] causing _____ in an individual 
with the FMR1 [premutation or intermediate/gray zone allele]?”  Conditions unrelated to 
FXS and its associated phenotypes included things like heart disease, kidney problems, 
uterine fibroids, diabetes, gastric reflux, and glaucoma. Conditions that were related to or 
potentially associated with FXS and its associated phenotypes included early menopause, 
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social anxiety, depression, and tremor/ataxia. Of one hundred eighty-four total participants, 
104-158 individuals answered these questions, and results will be based on this subgroup. 
These findings can be seen summarized in Figure 2.4. Results showed that for every 
condition except for tremor/ataxia, there was at least one person who stated that there was 
a 0% chance of developing the phenotype. The lowest risk for tremor/ataxia was listed to 
be 6%, meaning that there were no participants who thought there was a 0% chance of 
developing the condition. Additionally, at least one individual stated that the maximum 
chance for developing each condition was 95% or higher. The mean responses for the 
chance of developing the following conditions unrelated to FXS or its associated 
phenotypes were as follows: heart disease (26.3%), kidney problems (21%), uterine 
fibroids (30.2%), diabetes (21.3%), gastric reflux (33.6%), and glaucoma (21.7%). The 
mean responses for the chance of developing the following conditions related to FXS or 
thought to be related to FXS or its associated phenotypes were as follows: early menopause 
(57%), social anxiety (63.8%), depression (60.2%), and tremor/ataxia (51.9%). 
FXS and Reproductive Decision-Making 
Of 184 individuals who elaborated on his or her result and its effect on reproductive 
decision-making, 60/184 (32.6%) said that his or her result did not affect their reproductive 
decisions or that they had already finished having children when they received the result. 
Of those who responded that their reproductive decision did not change, 5/60 (12%) said 
that they had children the natural way knowing that they could pass on their premutation. 
Additionally, 20/184 (10.9%) said that they did not know about their premutation when 
they had children, and 5/20 (25%) of those individuals said that their reproductive decisions 
would have changed had they known about his or her result prior to having children. One 
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individual who was currently pregnant said, “if [sic] my second boy has a full mutation I 
will feel awful for not catching it earlier because I would not [have] had him.” Of the 
participants with the FMR1 premutation, 38/184 (20.7%) elected to not have more children, 
and 29/184 (15.8%) of individuals said that they sought the help of reproductive 
technologies. Some individuals (5/184 or 2.7%) were unable to have children because they 
had already undergone menopause when they received their results, 8/184 (4.3%) of 
participants sought out prenatal diagnosis with or without termination, and 9/184 (4.8%) 
stated that their reproductive decisions changed but did not specify how. Of the individuals 
with the FMR1 premutation, 15/184 (8.2%) were either unsure or did not answer the 
question (Figure 2.5B).  
Suggestions for Genetic Counseling 
We asked individuals for suggestions for genetic counseling for each of the various 
phenotypes associated with having the FMR1 premutation, such as FXTAS and FXPOI, 
but also for the potential psychiatric manifestations sometimes experienced by these 
individuals and some common themes emerged. In general, individuals asked for follow-
up appointments to receive the information in bits and pieces, as it is often too much to 
handle all at once. Additionally, they asked for referral to support resources and most 
importantly, they asked for honesty, kindness, compassion, and empathy, as there were 
individuals who were prepared for “doom and gloom” and given a negative outlook on the 
diagnosis as well as for the future. One individual said, “don’t [sic] say that everything is 
going to be negative and life is going to be a struggle,” and another said, “I think it is 
important to be compassionate yet fully honest with a person receiving a diagnosis. 
Watching my sister deal with FXPOI while trying to get pregnant was very hard.” 
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In terms of the individual associations, for the potential associated psychiatric 
manifestations, one respondent said, “ask [sic] if they have any psychiatric conditions, 
explain that it is a symptom of this condition and the reason for their trouble with it this 
whole time, and offer referrals for psychiatric/therapeutic evaluations.” Another said  
[The] genetic counselor should immediately point out the rates of depression, 
anxiety, etc. and ask the person if they’ve experienced this, [and then] point out that 
[the] diagnosis itself can bring on stress that can exacerbate or even cause these 
symptoms to arise, and that there are medications that can help. 
For FXPOI, individuals asked to be referred to a reproductive endocrinologist or other 
specialist and to cover some basics about the reproductive options that are available. A few 
participants asked for spouses to be included into the conversation with one saying “include 
spouses or significant others in the conversations. Don’t sugarcoat anything. Make the 
person aware that this is real.” Additionally, one individual stated that it is “very important 
to emphasize that this can have unpredictable ‘relapses’ so that if they do not want to get 
pregnant, they should still use contraception until full menopause.” Regarding counseling 
for FXTAS, individuals said that they would want to learn more about the full trajectory 
of the deterioration involved with having FXTAS as well as information on what are some 
of the warning signs. 
Fragile X-Associated Primary Ovarian Insufficiency (FXPOI) 
We asked two knowledge questions about FXPOI which can affect individuals with 
the FMR1 premutation. The first question asked the participants to choose all features 
associated with FXPOI. Of the individuals with the FMR1 premutation, 108/184 (58.7%) 
chose “menstrual cycle irregularities,” 100/184 (54.3%) chose “hormone fluctuations,” 
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116/184 (63%) chose “decreased fertility,” 135/184 (73.4%) chose “early onset 
menopause,” and 66/184 (35.9%) chose osteoporosis (Figure 2.8). 
The second knowledge question asked for the percentage of women with the FMR1 
premutation experience FXPOI. Results showed that 0/184 (0%) said 1%, 50/184 (27.2%) 
said 20%, 47/184 (25.5%) said 40%, 27/184 (14.7%) said 60%, 9/184 (4.9%) said 80% and 
1/184 (0.5%) said that there was a 100% chance of developing FXPOI if an individual has 
the FMR1 premutation (Figure 2.9A). Of these individuals, 50/184 (27.2%) did not answer 
the question. When asked if the individuals themselves have experienced FXPOI, 57/184 
(31%) said yes, 61/184 (33.2%) said no, 22/184 (12%) said that they were unsure, and 
44/184 (23.9%) chose not to answer the question (Figure 2.9D). Of those that were unsure, 
most stated that they had no formal diagnosis of FXPOI but needed to see a physician 
because they potentially were experiencing symptoms. When asked if anyone in the family 
had FXPOI, 51/184 (27.7%) said yes, 45/184 (24.5%) said no, 45/184 (24.5%) said that 
they were unsure, and 43/184 (23.4%) chose not to answer the question. Of those that were 
unsure, reasons cited were that they did not know their family history or have contact with 
relatives who may be experiencing this. Additionally, some stated that they were unsure 
because it had not come up in conversation with relatives and that there were some cases 
of infertility in the family but the cause was unknown. 
We surveyed participants about where/from whom and when they first learned 
about FXPOI being associated with the FMR1 premutation. Results are summarized in 
Figure 2.10. Regarding where or from whom they received results, 5/184 (2.7%) said “face 
to face support group,” 4/184 (2.2%) listed “books,” 17/184 (9.2%) listed “conversations 
with other [individuals with] a fragile X premutation,” 44/184 (23.9%) stated 
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“conversations with other healthcare providers,” 32/184 (17.4%) individuals listed 
“internet websites,” such as the National Fragile X Foundation website, 5/184 (2.7%) listed 
“online Facebook group,” and 6/184 (3.3%) listed “informational pamphlet.” In addition, 
7/184 (3.8%) stated “this has never been discussed with me,” 2/184 (1.1%) individuals 
listed “do not know/recall,” and 52/184 (28.3%) chose not to answer the question. Of the 
individuals with the FMR1 premutation, 10/184 (5.4%) listed “other,” which included 
which included five individuals who first read it on published scholarly articles/research 
meetings.  
Regarding when they first learned about FXPOI being associated with the FMR1 
premutation, 35/184 (19%) said “at the time I was found to be a premutation carrier,” 7/184 
(3.8%) said “at the time of my POI/POF diagnosis,” 6/184 (3.3%) stated “at the time of a 
family member’s POI/POF diagnosis,” 33/184 (17.9%) said “at the time of my child’s FXS 
diagnosis,” 8/184 (4.3%) listed “at the time of another family members’ FXS diagnosis,” 
and 29/184 (15.8%) listed “at another time” (Figure 2.11). Additionally, 14/184 (7.6%) 
individuals listed “this has never been discussed with me and 52/184 (28.3%) chose not to 
answer the question. Of those that listed “at another time,” responses included learned at a 
FXS conference or when doing research on one’s own, and one individual stated that she 
learned of FXPOI in graduate school. 
We also asked participants when they feel like the best time is for the healthcare 
provider to discuss the risks of FXPOI to an individual with the FMR1 premutation. Of the 
individuals with the FMR1 premutation, 94/184 (51%) of individuals stated that they would 
prefer this information at the time of diagnosis, while 5/184 (2.7%) said that they would 
prefer to receive this information a few months after diagnosis or at a follow-up 
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appointment. Some individuals gave specifics regarding when they would want to receive 
this information with 5/184 (2.7%) individuals saying that they would want to receive this 
information at the time of family planning, 1/184 (0.5%) individual stated that it should be 
mentioned at a yearly physical, and 3/184 (1.6%) mentioned that it should be revealed 
during puberty. Additionally, 7/184 (3.8%) either did not know or did not properly answer 
the question. 69/184 (37.5%) of individuals left this question blank (Figure 2.12).  
We sought to see which resources are most helpful for learning about FXPOI in 
relation to having the FMR1 premutation. Individuals could choose up to three resources 
which they found most helpful and results can be found in Figure 2.13. Of these 
participants, 24/184 (13%) listed “books”, 14/184 (7.6%) said “face to face support group,” 
71/184 (38.6%) said “conversations with other carriers of a fragile X premutation,” 77/184 
(41.8%) said “conversations with healthcare providers,” 75/184 (40.8%) listed “internet 
websites,” 57/184 (31%) listed “online Facebook group,” 28/184 (15.2%) listed 
“informational pamphlet,” and 6/184 (3.3%) listed “other.” 
Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS) 
We asked two knowledge questions about FXTAS which can affect individuals 
with the FMR1 premutation. The first question asked the participants to choose all features 
associated with FXTAS. Results showed that 66/184 (35.9%) chose “mood swings,” 
86/184 (46.7%) chose “dementia,” 112/184 (60.9%) chose “intention tremor,” 114/184 
(62%) chose “difficulty with balance,” and 101/184 (54.9%) chose “difficulty walking,” 
and 81/184 (44%) chose “numbness in extremities” (Figure 2.8B). 
The second knowledge question asked what percentage of men with the FMR1 
premutation experience FXTAS. Results showed that 3/184 (1.6%) said 1%, 68/184 (37%) 
44 
said 25%, 33/184 (17.9%) said 50%, 22/184 (12%) said 75%, and 0/184 (0%) said that 
there was a 100% chance of developing FXTAS if an individual has the FMR1 premutation 
(Figure 2.9B). Of these participants, 58/184 (31.5%) did not answer the question. When 
asked if the individuals themselves have experienced FXTAS, 6/184 (3.3%) said yes, 
120/184 (65.2%) said no, 3/184 (1.6%) said that they were unsure, and 55/184 (31.5%) 
chose not to answer the question (Figure 2.9D). When asked if anyone in the family had 
FXTAS, 23/184 (12.5%) said yes, 83/184 (45.1%) said no, 21/184 (11.4%) said that they 
were unsure, and 57/184 (31%) chose not to answer the question. Of those that were unsure, 
reasons cited were that they did not know their family history or have contact with relatives 
who may be experiencing this. Additionally, some stated that there was no formal diagnosis 
but there were symptoms present in one or more of his or her family members.  
We surveyed participants about where/from whom and when they first learned 
about FXTAS being associated with the FMR1 premutation. Results are summarized in 
Figure 2.10. Regarding where or from whom they received results, 1/184 (0.5%) said “face 
to face support group,” 4/184 (2.2%) listed “books,” 6/184 (3.3%) listed “conversations 
with other [individuals with] a fragile X premutation,” 35/184 (19%) stated “conversations 
with other healthcare providers,” 34/184 (18.5%) individuals listed “internet websites,” 
such as the National Fragile X Foundation website, 3/184 (1.6%) listed “online Facebook 
group,” and 8/184 (4.3%) listed “informational pamphlet.” 7/184 (3.8%) stated “this has 
never been discussed with me,” 7/184 (3.8%) individuals listed “do not know/recall,” and 
61/184 (33.2%) chose not to answer the question. Of these participants, 18/184 (9.8%) 
listed “other,” of which half (9/18) first read it on published scholarly articles/research 
meetings.  
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Regarding when they first learned about FXTAS being associated with the FMR1 
premutation, 29/184 (15.8%) said “at the time I was found to be a premutation carrier,” 
8/184 (4.3%) said “at the time of my FXTAS diagnosis,” 4/184 (2.2%) stated “at the time 
of a family member’s FXTAS diagnosis,” 25/184 (13.6%) said “at the time of my child’s 
FXS diagnosis,” 5/184 (2.7%) listed “at the time of another family members’ FXS 
diagnosis,” and 38/184 (20.7%) listed “at another time” (Figure 2.11). Additionally, 13/184 
(7.1%) individuals listed “this has never been discussed with me and 62/184 (33.7%) chose 
not to answer the question. Of those that listed “at another time,” responses included 
learned at a FXS conference or when doing research on one’s own. Additionally, one 
individual learned of FXTAS in graduate school.  
We also asked participants when they feel like the best time is for the healthcare 
provider to discuss the risks of FXTAS to an individual with the FMR1 premutation, of 
which 84/184 (45.7%) of individuals stated that they would prefer this information 
immediately or at the time of diagnosis, while 9/184 (4.9%) said that they would prefer to 
receive this information a few months after diagnosis or at a follow-up appointment. Of 
these individuals with the FMR1 premutation, 3/184 (1.6%) individuals said that they 
would want to receive this information if symptoms presented. In addition, 8/184 (4.3%) 
either did not know or did not properly answer the question and 80/184 (43.5%) of 
individuals left this question blank (Figure 2.12).  
We sought to see which resources are most helpful for learning about FXTAS in 
relation to having the FMR1 premutation. Individuals could choose up to three resources 
which they found most helpful and results can be found in Figure 2.13. Results show that 
21/184 (11.4%) listed “books”, 20/184 (10.9%) said “face to face support group,” 62/184 
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(33.7%) said “conversations with other carriers of a fragile X premutation,” 64/184 
(34.8%) said “conversations with healthcare providers,” 75/184 (40.8%) listed “internet 
websites,” 34/184 (23.4%) listed “online Facebook group,” 27/184 (14.7%) listed 
“informational pamphlet,” and 9/184 (4.9%) listed “other.” 
Fragile X Psychiatric Manifestations 
We asked two knowledge questions about the psychiatric manifestations that are 
potentially being seen in individuals with the FMR1 premutation. The first question asked 
the participants to choose all psychiatric features potentially associated with the FMR1 
premutation, with the knowledge that only two have been reported in the literature, 
depression, and anxiety (including social anxiety). Of the individuals with the FMR1 
premutation, 145/184 (78.8%) of participants listed depression and 150/184 (81.5%) listed 
anxiety as being associated with the FMR1 premutation (Figure 2.8C). We also included 
four conditions that have not been reported in the literature to be associated with the FMR1 
premutation, as well as some conditions that have not been found to have genetic causes 
or genetic associations for manifestation (schizophrenia, bipolar disorder, borderline 
personality disorder, and conduct disorder). Results showed that 13/184 (7.1%) listed 
schizophrenia, 29/184 (15.8%) listed bipolar disorder, 16/184 (8.7%) individuals listed 
borderline personality disorder, and 18/184 (9.8%) listed conduct disorder as being 
associated with having the FMR1 premutation (Figure 2.8C). In addition, 15/184 (8.2%) of 
individuals listed “other,” which included fibromyalgia, stress, phobias, OCD, ADHD, and 
effects in “social dynamics.” Only 3/184 (1.6%) of individuals stated that they did not think 
that there were any psychiatric manifestations associated with having the FMR1 
premutation. 
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The second knowledge question asked what percentage of individuals with the 
FMR1 premutation experience psychiatric manifestations (depression and anxiety) and 
7/184 (3.8%) stated 1%, 38/184 (20.7%) said 20%, 38/184 (20.7%) said 40%, 38/184 
(20.7%) said 60%, 27/184 (14.7%) said 80%, and 2/184 (1.1%) said 100% of women with 
the FMR1 premutation experience psychiatric manifestations, 34/184 (18.5%) of 
individuals chose not to answer this question (Figure 2.9C). When asked if the individuals 
themselves have experienced any psychiatric manifestations such as depression and/or 
anxiety, 120/184 (65.2%) said yes, 34/184 (18.5%) said no, 7/184 (3.8%) were unsure, and 
23/184 (12.5%) chose not to answer the question (Figure 2.9D). Of those that were unsure, 
many individuals stated that they have symptoms of depression and/or anxiety but are 
unsure whether it is due to having the FMR1 premutation or because of other stressors in 
life (e.g. having a child with FXS and/or receiving the premutation diagnosis). One 
respondent said, “It is depressing having a very low functioning high behavior demands 
kid…” while another said, “The stress and anxiety associated with discovering that you are 
a carrier and the implications have also triggered anxiety and depression – I don’t think 
this is related to the allele, it would be distressing news to anyone.” Regarding social 
anxiety, one individual stated “I’ve never been diagnosed with depression or anxiety, but I 
do seem to have some social anxiety. I don’t know what is a ‘normal’ or ‘standard’ level 
of social anxiety, however, and have never seen a therapist.” When asked if anyone in the 
family had experienced psychiatric manifestations (i.e. depression and/or anxiety), 125/184 
(67.9%) said yes, 22/184 (12%) said no, and 13/184 (7.1%) were unsure. Of those who 
were unsure, the main reason cited was that many family members showed symptoms but 
did not have a formal diagnosis of a psychiatric condition.  
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We surveyed participants about where/from whom and when they first learned 
about psychiatric manifestations potentially being associated with the FMR1 premutation. 
Results are summarized in Figure 2.10. Regarding where or from whom they received 
results, 2/184 (1.1%) said “face to face support group,” 3/184 (1.6%) listed “books,” 
18/184 (9.8%) listed “conversations with other [individuals with] a fragile X premutation,” 
21/184 (11.4%) stated “conversations with other healthcare providers,” 48/184 (26.1%) 
individuals listed “internet websites,” such as the National Fragile X Foundation website, 
16/184 (8.7%) listed “online Facebook group,” 9/184 (4.9%) listed “informational 
pamphlet,” 16/184 (8.7%) stated “this has never been discussed with me,” 3/184 (1.6%) 
individuals listed “do not know/recall,” and 32/184 (17.4%) chose not to answer the 
question. Additionally, 16/184 (8.7%) listed “other,” which included twelve individuals 
who first read it on published scholarly articles/research meetings. 
Regarding when they first learned about psychiatric manifestations potentially 
being associated with the FMR1 premutation, 39/184 (21.2%) said “at the time I was found 
to be a premutation carrier,” 3/184 (1.6%) said “at the time of my mental health diagnosis,” 
1/184 (0.5%) stated “at the time of a family member’s mental health diagnosis,” 28/184 
(15.2%) said “at the time of my child’s FXS diagnosis,” 14/184 (7.6%) stated “at the time 
of another family member’s FXS diagnosis,” 34/184 (18.5%) listed “at another time,” 
32/184 (17.4%) individuals listed “this has never been discussed with me, and 33/184 
(17.9%) chose not to answer the question (Figure 2.11). Of those that listed “at another 
time,” responses included learned at a FXS conference or when doing research on one’s 
own.  
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We also asked participants when they feel like the best time is for the healthcare 
provider to discuss the potential association between having the FMR1 premutation and 
psychiatric manifestations to an individual with the FMR1 premutation. Results showed 
that 106/184 (57.6%) of individuals stated that they would prefer this information at the 
time of diagnosis, while 18/184 (9.8%) said that they would prefer to receive this 
information a few months after diagnosis or at a follow-up appointment (Figure 2.12). 
Additionally, 3/184 (1.6%) participants said that individuals should be told about this if 
they themselves present with psychiatric symptoms, with one respondent stating the 
following: 
I wish I had been tested as a teenager when I was struggling with depression. After 
learning [that psychiatric manifestations and the FMR1 premutation] were 
associated, I felt like my entire life made sense, it just clicked. I always wondered 
why I felt so different, feeling depressed for no apparent reason. I also had trouble 
making friends and being in social situations with large groups.  
Some participants gave specific examples of when they would want to receive this 
information with 1/184 (0.5%) stating that they would want to receive this information at 
the time of family planning, 2/184 (1.1%) stated that it should be mentioned at a yearly 
physical, and 7/184 (3.8%) either did not know or did not properly answer the question. 
Additionally, 49/184 (26.6%) of individuals left this question blank.  
Our next research question sought to see which resources are most helpful for 
learning about the potential associations between psychiatric manifestations (i.e. 
depression and/or anxiety) and having the FMR1 premutation. Individuals could choose up 
to three resources which they found most helpful and results can be found in Figure 2.13. 
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Results showed that 36/184 (19.6%) listed “books”, 24/184 (13%) said “face to face 
support group,” 80/184 (43.5%) said “conversations with other carriers of a fragile X 
premutation,” 60/184 (32.6%) said “conversations with healthcare providers,” 73/184 
(39.7%) listed “internet websites,” 61/184 (33.2%) listed “online Facebook group,” and 
25/184 (13.6%) listed “informational pamphlet,” and 12/184 (6.5%) listed “other.” One 
individual listed that he or she does not seek out information and said the following: 
It’s hard to separate the life of caring for someone with FXS and its impact on your 
life as a carrier. In the end, nothing I go through is worse than my son’s diagnosis. 
Therefore, it’s hard to care enough to learn more about it. Chronic caregivers don’t 
put themselves first and the symptoms of being a carrier are closely aligned with 
the outcome of being a caregiver. 
Differences Between the Two Groups 
 To determine if there was a difference in psychiatric manifestations between 
individuals with the FMR1 premutation versus those with the intermediate/gray zone allele, 
data were analyzed using Pearson’s chi-square. Results showed that there was a 
significantly greater number of individuals with psychiatric manifestations in the FMR1 
intermediate/gray zone allele group than what would be expected (p<0.01). To determine 
if there was a difference in knowledge about FXS between the two groups, an ANOVA 
analysis was completed. For question one, “Who has the greatest chance of inheriting a 
fragile X premutation?” there were significantly more individuals with the FMR1 
premutation who answered it correctly than those with the intermediate/gray zone allele 
(p=0.01). However, for question two, “Who has the greatest chance of having a child with 
fragile X syndrome?” there was no statistically significant difference between the two 
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groups (p=0.08). Regarding the questions that were evaluated using a Likert scale which 
asked questions about both conditions that are typically seen in the general population as 
well as those that are seen in individuals with FXS or any of its associated phenotypes, 
ANOVA analyses revealed significant differences between the two groups for several of 
these conditions. Significantly more individuals with the premutation said that there was a 
higher chance for early menopause (p=0.02), social anxiety (p=0.01), depression (p=0.02), 
and tremor/ataxia (p=0.01) by having the FMR1 premutation. The means for these values 
were 57%, 63.8%, 60.2%, and 51.9%, respectively. 
DISCUSSION 
 This study had three main aims: (1) to learn what information individuals with the 
FMR1 premutation know about FXS and its known associated phenotypes, FXPOI and 
FXTAS, as well as the potential for psychiatric manifestations such as depression and 
anxiety, (2) to learn which symptoms, if any, individuals with the FMR1 intermediate/gray 
zone allele experience, and (3) which resources are most helpful for learning about the 
abovementioned features.   
Knowledge About FXS 
Results show that most individuals, both with the FMR1 premutation as well as the 
intermediate/gray zone allele, underwent FXS testing due to having a child with FXS. This 
is interesting as expansion to a full mutation in the next generation does not occur in 
individuals with the FMR1 intermediate/gray zone allele and there have been no reported 
cases of this, revealing that these individuals may have misinterpreted the question and 
may actually have a different genetic carrier status than was reported. However, it is 
unsurprising to know that this was the same for individuals with the FMR1 premutation, as 
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biological mothers of children with FXS are automatically said to have the premutation 
and are mainly getting testing for purposes of confirmation of the diagnosis.  
The fact that there is a statistically significant difference in knowledge between the 
two groups regarding the two knowledge questions about FXS ((1) Who has the greatest 
chance of inheriting a fragile X premutation, and (2) Who has the greatest chance of having 
a child with fragile X syndrome?) indicates that genetic counselors may need to place more 
emphasis on the inheritance of FXS for intermediate/gray zone allele carriers so that they 
too understand the risks for expansion and inheritance. Additionally, while more 
individuals with the FMR1 premutation answered the two knowledge questions correctly, 
there were still many individuals who did not, indicating that there may need to be more 
emphasis on the inheritance of FXS for this group as well.  
Individuals in both groups overestimated his or her chances for developing 
symptoms related to FXS and its associated phenotypes. Additionally, the fact that 
individuals in the intermediate/gray zone range thought that they were at a higher risk for 
symptoms that are typically associated with those who have the FMR1 premutation shows 
that we need to make intermediate allele carriers aware that their risk for these things are 
not higher due to their mutation status. Also, individuals in both groups said that there was 
a chance of developing conditions unrelated to FXS, making it imperative that counselors 
address the actual associations between the allele status and potential clinical associations. 
However, it cannot be ruled out that individuals may have thought that there was an 
association between his or her mutation status and symptoms unrelated to FXS such as 
uterine fibroids or gastric reflux simply because of the fact that the choice was there. 
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Suggestions for counseling included spacing out the information over multiple 
clinic visits. However, it can be tricky to do this in a clinical setting, especially for those 
who are receiving this news prenatally while undergoing carrier screening. Typically, these 
patients see the genetic counselor once throughout the course of the pregnancy unless other 
reasons indicate long term follow-up care. These individuals have children with FXS who 
are followed annually in genetics clinic, but it is not known how much information these 
parents receive about their own implications, and where the information is received. The 
majority of individuals underwent testing due to having a child with FXS, and it was 
mentioned that parents are trying to absorb so much material about the implications for 
their children that it is difficult to focus on the implications for themselves.  
 While a large number of individuals with the FMR1 premutation said that they 
experienced depression and/or anxiety, this is still not an association that can be made due 
to the presence of the FMR1 premutation. Although there have been reports in the literature 
about women experiencing these symptoms even without having a child affected with FXS, 
the possibility that these features can present due to life stressors or even other genetic and 
environmental contributions cannot be ruled out. Additionally, mood disturbances such as 
irritability and anger as well as psychiatric conditions such as depression and anxiety are 
associated with FXTAS, and a large number of individuals with the FMR1 premutation 
stated that they were “unsure” whether they had experienced FXTAS, which further makes 
this a possibility to consider. 
Intermediate/Gray Zone Features 
 Results show that approximately half of the participants with the FMR1 
intermediate/gray zone allele report experiencing depression and/or anxiety, but whether 
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they were diagnosed by a licensed mental health professional was not asked. The fact that 
there are significantly more individuals with the FMR1 intermediate/gray zone allele who 
experienced psychiatric manifestations than what would be expected shows that there may 
be an association between having the intermediate/gray zone allele and psychiatric 
manifestations, but more research needs to be done that would account for other intrinsic 
and extrinsic factors such as family history of mental illness, previous trauma/hardships, 
and susceptibility to mental illness due to other genetic factors. Although the numbers are 
statistically significant for this study in particular, the incidence of depression and anxiety 
are high in the general population, with about one in four individuals experiencing some 
type of serious mental illness over the course of his or her lifetime (“Mental Health by the 
Numbers, n.d.”). Therefore, based on our results, it is likely that depression and/or anxiety 
is not associated with the FMR1 intermediate/gray zone allele, but it is important to be 
mindful of these symptoms being more prevalent when counseling these individuals. 
Additionally, there have been no reports to date of depression or anxiety being associated 
with the FMR1 intermediate/gray zone allele, and more research needs to be done into the 
needs of these individuals. This manifestation could be due to the anxiety of having an 
intermediate/gray zone allele and some of the uncertainty that comes with that, although 
this study did not specifically delve into that aspect.  
While none of the participants with the FMR1 intermediate/gray zone allele report 
having experienced any Parkinsonism features, four individuals did report experiencing 
tremors. There may have been individuals who qualified for having experienced 
Parkinsonism features, but perhaps did not understand what some of the medical terms 
were (e.g. bradykinesia, resting tremor). Additionally, while the Parkinsonism features 
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have been observed in both males and females with the FMR1 intermediate/gray zone 
allele, most of what has been observed has been in males (Entezari, Khaniani, Bahrami, 
Derakhshan, & Darvish, 2017; Hall et al., 2011; Liu, Winarni, Zhang, Tassone, & 
Hagerman, 2013). Also, while many of these individuals do not have a clinical diagnosis 
of FXTAS, they did experience some of the features associated with it such as memory 
loss, tremors, ataxia, and gait abnormalities. This is interesting and poses an avenue for 
further research. 
Helpful Resources 
Individuals with the FMR1 premutation revealed that the most helpful resources to 
learn about FXS were Internet websites, conversations with healthcare providers, and 
conversations with other individuals with a FMR1 premutation. Online Facebook groups 
came in fourth and seemed to be most helpful for learning about FXPOI and the potential 
psychiatric manifestations associated with the FMR1 premutation, and that Internet 
websites (such as the National Fragile X Syndrome Foundation website) were most helpful 
for learning about FXTAS. Unsurprisingly, the most helpful resource regarding learning 
about the potential psychiatric manifestations associated with having the FMR1 
premutation was by having conversations with other individuals with the FMR1 
premutation. With the advent of social media, many individuals have found online 
Facebook groups to be helpful in not only learning information about FXS and its 
associated phenotypes, but also to connect with other individuals who share some of the 
same trials and tribulations as they do, which supports Leon Festinger’s social comparison 
theory. The theory recognizes that “people often rely on how they stand relative to other 
people to assess their opinions and potential,” and social comparison refers to “the search 
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for and utilization of information about other persons’ standings and opinions for the 
purpose of self-assessment…” (Lange, Kruglanski, & Higgins, 2012). Additionally, some 
of the participants who answered “conversations with other individuals with a Fragile X 
premutation” may have been doing so on an online Facebook group, which makes it a 
strong possibility that these Facebook groups could actually be even more helpful than the 
findings indicate. Regarding support for individuals with the FMR1 intermediate/gray zone 
allele, the majority of participants stated that they would be “likely” or “very likely” to 
utilize a support group to connect with other individuals with the intermediate/gray zone 
allele, especially since online Facebook support groups specifically tailored to this 
population do not currently exist. The creation of one of these groups may be necessary in 
the future to provide a medium for these individuals to learn more about the ongoing 
research as well as connect with others in a similar situation to themselves. 
Study Limitations 
Although sample size provided adequate power to detect statistical differences, 
some limitations to the study do exist. First, the Facebook groups by which the participants 
were recruited contain large numbers of individuals and it is likely that only individuals 
who are interested in research regarding FXS were the ones who participated. Therefore, 
our study population may not be representative of all individuals who have the FMR1 
premutation or the FMR1 intermediate/gray zone allele. It is also likely that there was 
sampling bias regarding individuals in the intermediate/gray zone range, as 
intermediate/gray zone allele carriers who are experiencing symptoms may be the ones to 
be involved in these Facebook groups. Third, since these participants were recruited 
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through Facebook groups with most of these groups being support groups, the findings that 
online support groups are one of the more beneficial resources may be skewed.  
The demographic make-up of the participants was homogeneous and was not 
representative of the general population, primarily with regards to gender and educational 
level. Most individuals were female and most of them had some college education or 
higher. The fact that the vast majority of participants were female made it more difficult to 
interpret the responses to questions regarding FXTAS, as it primarily affects males. The 
Parkinsonism features that have been observed in individuals with the FMR1 intermediate 
allele have primarily been observed in males as well, so having a paucity of males in this 
study does not rule out the fact that there could be other individuals with the 
intermediate/gray zone allele that are manifesting Parkinsonism features. However, due to 
the large number of individuals that did not respond to the question regarding whether they 
were male or female, there is a possibility that many of those individuals were males. 
Additionally, since the majority of participants were female and females have a higher 
incidence of internalizing anxiety and depression than males, the findings that there was a 
high incidence of these psychiatric manifestations may be due to this (Eaton et al., 2012).  
Another point to consider is that the knowledge base of the participants may not 
have been entirely reflective of the individuals’ counseling experience. For one, the 
participants came from a variety of different countries, and there may be variation in the 
counseling and information provided about FXS between countries. Also, the time points 
at which people learned about the inheritance of FXS as well as its associations may not 
reflect the information given to them at the time of diagnosis. For example, FXTAS was 
discovered in the early 2000s, so people who received their mutation status prior to this 
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would likely not have been counseled about this association. Another thing to consider is 
that many of the participants may have pretty good knowledge of the inheritance patterns/ 
features now, but what about right after the diagnosis? Families of older children might 
have had this diagnosis for 10-20 years and have had plenty of time to do reading on their 
own, talk with other families, etc. and answer the survey questions based on this current 
knowledge. 
Additionally, the majority of the questions in this study were based on self-report, 
which could also skew the data. Individuals who stated that they have tremors, ataxia, 
depression, anxiety, or any of the other features surveyed in this study may not have a 
formal diagnosis by a healthcare provider. Additionally, there may exist some confusion 
regarding the terminology of FXS and its features. Anecdotal evidence of the researchers 
shows that some women with the FMR1 full mutation who do not have intellectual 
disability consider themselves to be carriers and may have filled out the survey as such.  
Lastly, it is important to point out that there were a significant number of 
individuals, especially in the premutation group, that did not answer all of the questions in 
the survey. Many of the questions were left blank and may not accurately reflect the results 
for the group as a whole. These included basic questions such as those asking for 
demographic information as well as more detailed questions regarding most helpful 
resources and suggestions for genetic counseling. Therefore, the results may not be entirely 
reflective of the participants in that group. One reason for this lack of response may have 
been due to the length as well as repetitiveness of the survey, as most all of these questions 




These results highlight the importance of genetic counseling for both individuals 
with the FMR1 premutation as well as those that are intermediate/gray zone allele carriers. 
Although significantly more individuals with the FMR1 premutation correctly answered 
the general knowledge questions correctly than those in the intermediate/gray zone allele 
range, there were still several people who do not understand the genetics of FXS. This 
makes it even more important for genetic counselors to take extra measures to ensure that 
his or her patients are understanding the inheritance, as individuals in both groups are 
basing reproductive decision-making on their understanding of results.  
Additionally, while this research does not find a significant increase in psychiatric 
manifestations in individuals with the FMR1 premutation than what would be expected, 
the fact that these conditions exist in this population cannot be disputed, and it is important 
to address these issues in clinic. Some individuals stated that they felt relieved when they 
learned of the potential association between having the premutation and psychiatric 
manifestations, as it made them not feel “weak” and allowed them to re-frame their 
problems to consider a potential genetic component.  
Lastly, learning that Internet websites, conversations with healthcare providers and 
conversations with other individuals with a FMR1 premutation are most beneficial for 
learning about FXS, genetic counselors and other healthcare providers can refer their 
patients to these resources upon diagnosis of a premutation or an FMR1 intermediate allele. 
With the advent of social media, many individuals have found online Facebook groups to 
be helpful in not only learning information about FXS and its associated phenotypes, but 
also to connect with other individuals in a community of support. This is something to be 
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mindful of since in addition to online websites, most practices offer handouts and 
informational packets as resources, but distributing names of some of the online Facebook 
groups may be even more beneficial to our patients. Additionally, in practice, it may be 
beneficial for genetic counselors and other healthcare providers to ask patients what types 
of resources would be most helpful for his or her particular learning style, and then tailor 
the distribution of those resources accordingly. 
Research Recommendations 
Future research could explore the phenomenon of AGG interruptions in individuals 
with the FMR1 premutation. Research has shown that the presence of one or more AGG 
interruptions can reduce the risk for expansion in premutation alleles (Nolin et al, 2013; 
Latham, Coppinger, Hadd, & Nolin, 2014; Nolin et al, 2015). Therefore, it would be 
interesting to see whether women underwent further testing to learn their AGG status and 
if having AGG interruptions affected their decisions to have more children. Along with 
that, it would be interesting to learn whether assistive reproductive technologies were 
utilized or if conception was natural.  
Knowledge about FXS is continuously evolving as more research is being done. 
Future research could ascertain participants’ knowledge of inheritance and associated 
phenotypes right after diagnosis, as well as during certain time points to better control for 
the variable of time. Regarding research for individuals with the FMR1 intermediate/gray 
zone allele, it would be beneficial to know where they are learning about the risks, if any, 
of having this allele. Current practice guidelines do not state that there are any risks 
associated with having the intermediate/gray zone allele, besides the risk for expansion in 
future generations (Finucane et al., 2012). However, individuals are attending conferences 
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and are reading the publications in the literature about the potential associations and survey 
responses showed that some of the individuals also learned of some potential clinical 
consequences from their doctors. Genetic counselors and other healthcare providers need 
to be able to stay on top of the research being done in order to answer questions if they 
arise.  
This study aimed to see if individuals with the FMR1 premutation experienced any 
psychiatric manifestations such as depression or anxiety, as those two have been 
documented in the form of case reports in the literature. However, this association is not 
yet known and further research needs to continue be done to see whether there is, in fact, a 
need to counsel about the potential for these features as well. Anecdotal evidence of the 
researcher herself has shown that many mothers of children with FXS post on social media 
about their anxiety and wonder whether it is related to them having the FMR1 premutation, 
and the research continues to show conflicting evidence. It would be beneficial to continue 
to study this population to ascertain this potential association even further. It would also be 
helpful to screen for depression and anxiety at the time of diagnosis, as many individuals 
may already be experiencing these features and genetic counselors can help steer these 
individuals to support as needed. Additionally, future research should consider the 
limitations proposed by this study and seek to improve upon them, such as having a sample 
size more representative of the general population, as well as recruiting from a multitude 
of other sources.  
Conclusion 
 FXS is a complex genetic disorder and involves numerous facets that require proper 
education and follow-up. While many individuals with the FMR1 premutation are 
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knowledgeable about the basic inheritance of FXS as well as its associated phenotypes, it 
is important for genetic counselors to review this information in detail with both individuals 
with the FMR1 premutation as well as those with the intermediate/gray zone allele. 
Additionally, while there are no established associations between psychiatric 
manifestations and the FMR1 premutation, it is important to know that many of these 
individuals, as well as those with the intermediate/gray zone allele, are experiencing these 
symptoms and may need additional care beyond the scope of our practice. We as genetic 
counselors are well trained to not only delve into the psychosocial realm of these patient’s 
experiences, but also provide resources that are best suited to their needs. With the advent 
of social media, many individuals are turning to online resources for support and a sense 
of community, and genetic counselors can use this knowledge to steer patients to resources 
that would be most beneficial for them. 
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Table 2.1 Molecular Classification and Clinical Manifestations Based on # of CGG 




# of Repeats Clinical Phenotype 




Potential Parkinsonism and neuropsychiatric 
features (later in life) 
Premutation 55-200 
Fragile X-associated Tremor/Ataxia Syndrome 
(FXTAS), Fragile X-associated Primary 
Ovarian Insufficiency (FXPOI) in females, 
potential for psychiatric manifestations (i.e. 
depression, anxiety) 
Full Mutation >200 








































Men 3 3 
Women 21 124 
Did Not Answer 6 57 
Country of 
Residence 
In the United States 15 66 
Outside of the 
United States 
15 62 
Did Not Answer 0 56 
Education 
Less than High 
School 
1 2 






Vocational, or Trade 
School 
9 26 




Did Not Answer 5 56 









Figure 2.1 All participants were asked their reasons for being tested for the FMR1 premutation, the year of diagnosis, as well as questions 
regarding when they were last had a formal discussion regarding FXS and its implications with a healthcare provider. The year 1991 is 
of importance as that is when the FMR1 gene was discovered and a name was given to the condition. 
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Figure 2.2 Responses for individuals with the FMR1 premutation and for intermediate/gray zone allele carriers for two general 
knowledge questions regarding the inheritance of Fragile X syndrome: Who has the greatest chance of inheriting a Fragile X 
Premutation?” and “Who has the greatest chance of having a child with Fragile X syndrome?” The correct answers are “Daughter of a 
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Figures 2.3 Depiction of “correct” and “incorrect” answers for the two general knowledge 
questions: (1) Who has the greatest chance of inheriting a fragile X premutation, and (2) 
Who has the greatest chance of having a child with fragile X syndrome? (A) Responses for 
question 1 for intermediate/gray zone allele carriers, showing that 23% of individuals with 
the intermediate/gray zone allele answered the question correctly. (B) Responses for 
question 1 for individuals with the FMR1 premutation, depicting that 51% of individuals 
with the FMR1 premutation answered the question correctly. (C) Responses for question 2 
for intermediate/gray zone allele carriers, showing that 43% of individuals with the 
intermediate/gray zone allele answered the question correctly. (D) Responses for question 
2 for individuals with the FMR1 premutation, depicting that 64% of individuals with the 

































Figure 2.4 Box and whisker plot depicting individuals’ responses regarding the likelihood (from 0%-100%) of developing conditions 
observed in the general population, as well as those that are or may be associated with having an FMR1 premutation or intermediate 
allele.





Figure 2.5 Effects of the FMR1 intermediate/gray zone allele (A) and the FMR1 
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Figure 2.6 Intermediate/gray zone allele carriers’ responses regarding whether they 
themselves have experienced any/all of the following: depression, anxiety, memory loss, 
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Figure 2.7 Intermediate/gray zone allele carriers’ likelihood of utilizing a support group. 
24/30 (80%) of individuals with the FMR1 intermediate/gray zone allele said that they 






















   
 
Figure 2.8 Participants’ responses when asked to choose any and all features associated with either (A) FXPOI, (B) FXTAS, or (C) FX 
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Figure 2.9 Responses to knowledge questions regarding the percentage of individuals with the FMR1 premutation who will experience 
(A) FXPOI, (B) FXTAS, and (C) FX psychiatric manifestations, with the correct answers being 20%, 50%, and 40%, respectively. (D) 
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Figure 2.10 184 individuals with the FMR1 premutation were asked to provide information regarding which source notified them of the 
association between having the premutation and FXPOI, FXTAS, and the potential FX psychiatric manifestations. The overall consensus 
shows that individuals first learned of this information on Internet websites, conversations with other healthcare providers, and 
conversations with other individuals with the FMR1 premutation. 
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Figure 2.11 184 individuals with the FMR1 premutation were asked to provide information regarding when they were first notified of 
the association between having the premutation and FXPOI, FXTAS, and the potential FX psychiatric manifestations. The overall 
consensus shows that individuals first learned of this information at the time of his or her own diagnosis of having the FMR1 premutation, 
at the time of his or her child’s diagnosis of FXS, or at another time (which, of those who elaborated, primarily involved attendance at 
regional and national FXS conferences).  
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Figure 2.12 184 individuals with the FMR1 premutation were asked what time is most helpful for learning about FXS and its associated 
phenotypes, and ~100 individuals (>50%) indicated that they would like to learn about these other conditions at the time of diagnosis, 
while only a few wanted to learn this information at a follow-up appointment. Some of those who stated “other” mentioned learning 
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Figure 2.13 Individuals with the FMR1 premutation were instructed to choose up to three (3) resources which they found most helpful 
for learning about FXPOI, FXTAS, and the psychiatric manifestations that may potentially be associated with having the FMR1 
premutation. Consensus shows that internet websites (such as the National FXS Foundation website, as well as other reputable sources), 
conversations with other healthcare providers, and conversations with other individuals with the FMR1 premutation are most helpful for 
learning more information about FXS and its associated phenotypes. 
0 50 100 150 200 250
Books
Face to Face Support Group
Conversations with Other Individuals with a Fragile X Premutation




















American College of Obstetricians and Gynecologists Committee on Genetics. (2010). 
ACOG Committee Opinion No.469: Carrier screening for fragile X syndrome. 
Obstetrics & Gynecology, 116, 1008–1010.  
 
Bacalman, S., Farzin, F., Bourgeois, J. A., Cogswell, J., Goodlin-Jones, B. L., Gane, L. W., 
… Hagerman, R. J. (2006). Psychiatric phenotype of the fragile X-associated 
tremor/ataxia syndrome (FXTAS) in males: newly described fronto-subcortical 
dementia. The Journal of Clinical Psychiatry, 67(1), 87–94. 
 
Barasoain, M., Barrenetxea, G., Huerta, I., Télez, M., Criado, B., & Arrieta, I. (2016). 
Study of the genetic etiology of primary ovarian insufficiency: FMR1 
gene. Genes, 7(12). https://doi.org/10.3390/genes7120123 
 
Beard, C. A., Amor, D. J., Di Pietro, L., & Archibald, A. D. (2016). “I’m Healthy, It’s Not 
Going to Be Me”: Exploring experiences of carriers identified through a population 
reproductive genetic carrier screening panel in Australia. American Journal of 
Medical Genetics. Part A, 170(8), 2052–2059. 
https://doi.org/10.1002/ajmg.a.37697 
 
Bennett, C. E., Conway, G. S., Macpherson, J. N., Jacobs, P. A., & Murray, A. (2010). 
Intermediate sized CGG repeats are not a common cause of idiopathic premature 
ovarian failure. Human Reproduction (Oxford, England), 25(5), 1335–1338. 
https://doi.org/10.1093/humrep/deq058 
 
Biancalana, V., Glaeser, D., McQuaid, S., & Steinbach, P. (2015). EMQN best practice 
guidelines for the molecular genetic testing and reporting of fragile X syndrome 
and other fragile X-associated disorders. European Journal of Human Genetics: 
EJHG, 23(4), 417–425. https://doi.org/10.1038/ejhg.2014.185 
 
Bodega, B., Bione, S., Dalprà, L., Toniolo, D., Ornaghi, F., Vegetti, W., … Marozzi, A. 
(2006). Influence of intermediate and uninterrupted FMR1 CGG expansions in 
premature ovarian failure manifestation. Human Reproduction (Oxford, 
England), 21(4), 952–957. https://doi.org/10.1093/humrep/dei432 
 
Bourgeois, J. A., Coffey, S. M., Rivera, S. M., Hessl, D., Gane, L. W., Tassone, F., … 
Hagerman, R. J. (2009). A review of fragile X premutation disorders: expanding 




Bourgeois, J. A., Seritan, A. L., Casillas, E. M., Hessl, D., Schneider, A., Yang, Y., … 
Hagerman, R. J. (2011). Lifetime prevalence of mood and anxiety disorders in 
fragile X premutation carriers. The Journal of Clinical Psychiatry, 72(2), 175–182. 
https://doi.org/10.4088/JCP.09m05407blu 
Bretherick, K. L., Fluker, M. R., & Robinson, W. P. (2005). FMR1 repeat sizes in the gray 
zone and high end of the normal range are associated with premature ovarian 
failure. Human Genetics, 117(4), 376–382. https://doi.org/10.1007/s00439-005-
1326-8 
 
Coffey, S. M., Cook, K., Tartaglia, N., Tassone, F., Nguyen, D. V., Pan, R., … Hagerman, 
R. J. (2008). Expanded clinical phenotype of women with the FMR1 
premutation. American Journal of Medical Genetics. Part A, 146A (8), 1009–1016. 
https://doi.org/10.1002/ajmg.a.32060 
 
Connon, P., & Larner, A. J. (2017). Fragile X-associated tremor/ataxia syndrome: 
cognitive presentations. British Journal of Hospital Medicine (London, England: 
2005), 78(4), 230–231. https://doi.org/10.12968/hmed.2017.78.4.230 
 
Cornish, K., Turk, J., & Hagerman, R. (2008). The fragile X continuum: new advances and 
perspectives. Journal of Intellectual Disability Research: JIDR, 52(Pt 6), 469–482. 
https://doi.org/10.1111/j.1365-2788.2008.01056.x 
 
Cronister, A., Schreiner, R., Wittenberger, M., Amiri, K., Harris, K., & Hagerman, R. J. 
(1991). Heterozygous fragile X female: historical, physical, cognitive, and 
cytogenetic features. American Journal of Medical Genetics, 38(2–3), 269–274. 
 
Debrey, S. M., Leehey, M. A., Klepitskaya, O., Filley, C. M., Shah, R. C., Kluger, B., … 
Hall, D. A. (2016). Clinical phenotype of adult fragile X gray zone allele carriers: 
A case series. Cerebellum (London, England), 15(5), 623–631. 
https://doi.org/10.1007/s12311-016-0809-6 
 
Dillman, D. A., Smyth, J. D., & Christian, L. M. (2014). Internet, Phone, Mail, and Mixed-
Mode Surveys: The Tailored Design Method. John Wiley & Sons. 
 
Eaton, N. R., Keyes, K. M., Krueger, R. F., Balsis, S., Skodol, A. E., Markon, K. E., … 
Hasin, D. S. (2012). An invariant dimensional liability model of gender differences 
in mental disorder prevalence: evidence from a national sample. Journal of 
Abnormal Psychology, 121(1), 282–288. https://doi.org/10.1037/a0024780 
 
Entezari, A., Khaniani, M. S., Bahrami, T., Derakhshan, S. M., & Darvish, H. (2017). 
Screening for intermediate CGG alleles of FMR1 gene in male Iranian patients 
with Parkinsonism. Neurological Sciences: Official Journal of the Italian 
Neurological Society and of the Italian Society of Clinical 
Neurophysiology, 38(1), 123–128. https://doi.org/10.1007/s10072-016-2723-6 
 
80 
Espinel, W., Charen, K., Huddleston, L., Visootsak, J., & Sherman, S. (2016). Improving 
health education for women who carry an FMR1 premutation. Journal of Genetic 
Counseling, 25(2), 228–238. https://doi.org/10.1007/s10897-015-9862-4 
 
Finucane, B., Abrams, L., Cronister, A., Archibald, A. D., Bennett, R. L., & McConkie-
Rosell, A. (2012). Genetic counseling and testing for FMR1 gene mutations: 
practice guidelines of the national society of genetic counselors. Journal of Genetic 
Counseling, 21(6), 752–760. https://doi.org/10.1007/s10897-012-9524-8 
 
Finucane, B., Lincoln, S., Bailey, L., & Martin, C. L. (2017). Prognostic dilemmas and 
genetic counseling for prenatally detected fragile X gene expansions. Prenatal 
Diagnosis, 37(1), 37–42. https://doi.org/10.1002/pd.4963 
 
Fragile X Syndrome. (2017). Retrieved January 20, 2018, from https://fragilex.org/learn/ 
 
Fu, Y. H., Kuhl, D. P., Pizzuti, A., Pieretti, M., Sutcliffe, J. S., Richards, S., … Warren, S. 
T. (1991). Variation of the CGG repeat at the fragile X site results in genetic 
instability: resolution of the Sherman paradox. Cell, 67(6), 1047–1058. 
 
Gossett, A., Sansone, S., Schneider, A., Johnston, C., Hagerman, R., Tassone, F., … Hessl, 
D. (2016). Psychiatric disorders among women with the fragile X premutation 
without children affected by fragile X syndrome. American Journal of Medical 
Genetics. Part B, Neuropsychiatric Genetics: The Official Publication of the 
International Society of Psychiatric Genetics, 171(8), 1139–1147. 
https://doi.org/10.1002/ajmg.b.32496 
 
Grigsby, J., Brega, A. G., Bennett, R. E., Bourgeois, J. A., Seritan, A. L., Goodrich, G. 
K., & Hagerman, R. J. (2016). Clinically significant psychiatric symptoms among 
male carriers of the fragile X premutation, with and without FXTAS, and the 
mediating influence of executive functioning. The Clinical 
Neuropsychologist, 30(6), 944–959. 
https://doi.org/10.1080/13854046.2016.1185100 
Hagerman, R. J., & Hagerman, P. J. (2002). Fragile X Syndrome: Diagnosis, Treatment, 
and Research. Taylor & Francis US. 
 
Hagerman, R., & Hagerman, P. (2013). Advances in clinical and molecular understanding 
of the FMR1 premutation and fragile X-associated tremor/ataxia syndrome. The 
Lancet. Neurology, 12(8), 786–798. https://doi.org/10.1016/S1474-
4422(13)70125-X 
 
Hagerman, R. J., Leehey, M., Heinrichs, W., Tassone, F., Wilson, R., Hills, J., … 
Hagerman, P. J. (2001). Intention tremor, parkinsonism, and generalized brain 




Hall, D. A., Berry-Kravis, E., Zhang, W., Tassone, F., Spector, E., Zerbe, G., … Leehey, 
M. A. (2011). FMR1 gray zone alleles: Association with Parkinson disease in 
women? Movement Disorders: Official Journal of the Movement Disorder 
Society, 26(10), 1900. https://doi.org/10.1002/mds.23755 
 
Hall, D. A. (2014). In the gray zone in the fragile X gene: What are the key unanswered 
clinical and biological questions? Tremor and Other Hyperkinetic Movements 
(New York, N.Y.), 4, 208. https://doi.org/10.7916/D8NG4NP3 
 
Hall, D., Tassone, F., Klepitskaya, O., & Leehey, M. (2012). Fragile X-associated tremor 
ataxia syndrome in FMR1 gray zone allele carriers. Movement Disorders: Official 
Journal of the Movement Disorder Society, 27(2), 296–300. 
https://doi.org/10.1002/mds.24021 
 
Hoyos, L. R., & Thakur, M. (2017). Fragile X premutation in women: recognizing the 
health challenges beyond primary ovarian insufficiency. Journal of Assisted 
Reproduction and Genetics, 34(3), 315–323. https://doi.org/10.1007/s10815-016-
0854-6 
 
Hunter, J., Rivero-Arias, O., Angelov, A., Kim, E., Fotheringham, I., & Leal, J. (2014). 
Epidemiology of fragile X syndrome: a systematic review and meta-
analysis. American Journal of Medical Genetics. Part A, 164A(7), 1648–1658. 
https://doi.org/10.1002/ajmg.a.36511 
 
Jacquemont, S., Hagerman, R. J., Leehey, M. A., Hall, D. A., Levine, R. A., Brunberg, J. 
A., … Hagerman, P. J. (2004). Penetrance of the fragile X-associated tremor/ataxia 
syndrome in a premutation carrier population. JAMA, 291(4), 460–469. 
https://doi.org/10.1001/jama.291.4.460 
 
Juncos, J. L., Lazarus, J. T., Graves-Allen, E., Shubeck, L., Rusin, M., Novak, G., … 
Sherman, S. L. (2011). New clinical findings in the fragile X-associated tremor 
ataxia syndrome (FXTAS). Neurogenetics, 12(2), 123–135. 
https://doi.org/10.1007/s10048-010-0270-5 
 
Kenna, H. A., Tartter, M., Hall, S. S., Lightbody, A. A., Nguyen, Q., de los Angeles, C. P., 
… Rasgon, N. L. (2013). High rates of comorbid depressive and anxiety disorders 
among women with premutation of the FMR1 gene. American Journal of Medical 
Genetics. Part B, Neuropsychiatric Genetics: The Official Publication of the 
International Society of Psychiatric Genetics, 162B(8), 872–878. 
https://doi.org/10.1002/ajmg.b.32196 
 
Klusek, J., Martin, G. E., & Losh, M. (2014). Consistency between research and clinical 
diagnoses of autism among boys and girls with fragile X syndrome. Journal of 




Kronquist, K. E., Sherman, S. L., & Spector, E. B. (2008). Clinical significance of tri-
nucleotide repeats in Fragile X testing: a clarification of American College of 
Medical Genetics guidelines. Genetics in Medicine: Official Journal of the 
American College of Medical Genetics, 10(11), 845–847. 
https://doi.org/10.1097/GIM.0b013e31818b0c8a 
 
Lange, P. A. M. V., Kruglanski, A. W., & Higgins, E. T. (2012). Handbook of Theories 
of Social Psychology: Volume One. SAGE Publications. 
 
Latham, G. J., Coppinger, J., Hadd, A. G., & Nolin, S. L. (2014). The role of AGG 
interruptions in fragile X repeat expansions: a twenty-year perspective. Frontiers 
in Genetics, 5, 244. https://doi.org/10.3389/fgene.2014.00244 
Liu, Y., Winarni, T. I., Zhang, L., Tassone, F., & Hagerman, R. J. (2013). Fragile X-
associated tremor/ataxia syndrome (FXTAS) in grey zone carriers. Clinical 
Genetics, 84(1), 74–77. https://doi.org/10.1111/cge.12026 
 
López-Mourelo, O., Mur, E., Madrigal, I., Alvarez-Mora, M. I., Gómez-Ansón, B., 
Pagonabarraga, J., … Milà, M. (2017). Social anxiety and autism spectrum traits 
among adult FMR1 premutation carriers. Clinical Genetics, 91(1), 111–114. 
https://doi.org/10.1111/cge.12791 
 
Maddalena, A., Richards, C. S., McGinniss, M. J., Brothman, A., Desnick, R. J., Grier, R. 
E., … Wolff, D. J. (2001). Technical standards and guidelines for fragile X: the 
first of a series of disease-specific supplements to the Standards and Guidelines for 
Clinical Genetics Laboratories of the American College of Medical Genetics. 
Quality Assurance Subcommittee of the Laboratory Practice Committee. Genetics 
in Medicine: Official Journal of the American College of Medical Genetics, 3(3), 
200–205. https://doi.org/10.109700125817-200105000-00010 
 
Mailick, M., Greenberg, J., Smith, L., Sterling, A., Brady, N., Warren, S., & Hong, J. 
(2014). Fragile X–Associated Disorders. In J. Burack & L. Schmidt 
(Eds.), Cultural and Contextual Perspectives on Developmental Risk and Well-
Being (Interdisciplinary Approaches to Knowledge and Development, pp. 221-
253). Cambridge: Cambridge University Press. 
doi:10.1017/CBO9780511920165.015 
 
Mental Health By the Numbers | NAMI: National Alliance on Mental Illness. (n.d.). 
Retrieved April 5, 2018, from https://www.nami.org/learn-more/mental-health-by-
the-numbers 
 
Metterville, D.R. (2009). Assessing fragile X premutation carriers’ knowledge of the 
premutation phenotype. Unpublished manuscript, Biology Department and Genetic 
Counseling Program, Brandeis University, Massachusetts, United States. 
Monaghan, K. G., Lyon, E., Spector, E. B., & American College of Medical Genetics and 
Genomics. (2013). ACMG Standards and Guidelines for fragile X testing: a 
 
83 
revision to the disease-specific supplements to the Standards and Guidelines for 
Clinical Genetics Laboratories of the American College of Medical Genetics and 
Genomics. Genetics in Medicine: Official Journal of the American College of 
Medical Genetics, 15(7), 575–586. https://doi.org/10.1038/gim.2013.61 
Murray, A., Ennis, S., MacSwiney, F., Webb, J., & Morton, N. E. (2000). Reproductive 
and menstrual history of females with fragile X expansions. European Journal of 
Human Genetics: EJHG, 8(4), 247–252. https://doi.org/10.1038/sj.ejhg.5200451 
 
Murray, A., Schoemaker, M. J., Bennett, C. E., Ennis, S., Macpherson, J. N., Jones, M., … 
Swerdlow, A. J. (2014). Population-based estimates of the prevalence of FMR1 
expansion mutations in women with early menopause and primary ovarian 
insufficiency. Genetics in Medicine: Official Journal of the American College of 
Medical Genetics, 16(1), 19–24. https://doi.org/10.1038/gim.2013.64 
 
NCI Dictionary of Cancer Terms. (n.d.). Definition of genetic anticipation. Retrieved 
December 11, 2017, 
from https://www.cancer.gov/publications/dictionaries/genetics-dictionary 
Niu, M., Han, Y., Dy, A. B. C., Du, J., Jin, H., Qin, J., … Hagerman, R. J. (2017). Autism 
symptoms in fragile X syndrome. Journal of Child Neurology, 883073817712875. 
https://doi.org/10.1177/0883073817712875 
 
Nolin, S. L., Glicksman, A., Ding, X., Ersalesi, N., Brown, W. T., Sherman, S. L., & 
Dobkin, C. (2011). Fragile X analysis of 1112 prenatal samples from 1991 to 
2010. Prenatal Diagnosis, 31(10), 925–931. https://doi.org/10.1002/pd.2815 
 
Nolin, S. L., Glicksman, A., Ersalesi, N., Dobkin, C., Brown, W. T., Cao, R., … Hadd, A. 
G. (2015). Fragile X full mutation expansions are inhibited by one or more AGG 
interruptions in premutation carriers. Genetics in Medicine: Official Journal of the 
American College of Medical Genetics, 17(5), 358–364. 
https://doi.org/10.1038/gim.2014.106 
Nolin, S. L., Sah, S., Glicksman, A., Sherman, S. L., Allen, E., Berry-Kravis, E., … Hadd, 
A. G. (2013). Fragile X AGG analysis provides new risk predictions for 45-69 
repeat alleles. American Journal of Medical Genetics. Part A, 161A(4), 771–778. 
https://doi.org/10.1002/ajmg.a.35833 
 
Noto, V., Harrity, C., Walsh, D., & Marron, K. (2016). The impact of FMR1 gene 
mutations on human reproduction and development: a systematic review. Journal 
of Assisted Reproduction and Genetics, 33(9), 1135–1147. 
https://doi.org/10.1007/s10815-016-0765-6 
 
Pastore, L. M., Young, S. L., Baker, V. L., Karns, L. B., Williams, C. D., & Silverman, L. 
M. (2012). Elevated prevalence of 35-44 FMR1 trinucleotide repeats in women 
with diminished ovarian reserve. Reproductive Sciences (Thousand Oaks, 
Calif.), 19(11), 1226–1231. https://doi.org/10.1177/1933719112446074 
 
84 
Practice Guidelines Committee (2016). NSGC evidence-based clinical practice guideline 
development manual (A living document). 22–28, 34. 
Roberts, J. E., Tonnsen, B. L., McCary, L. M., Ford, A. L., Golden, R. N., & Bailey, D. B. 
(2016). Trajectory and predictors of depression and anxiety disorders in mothers 
with the FMR1 premutation. Biological Psychiatry, 79(10), 850–857. 
https://doi.org/10.1016/j.biopsych.2015.07.015 
 
Rocha, H. M., Savatt, J. M., Riggs, E. R., Wagner, J. K., Faucett, W. A., & Martin, C. L. 
(2017). Incorporating social media into your support tool box: Points to consider 
from genetics-based communities. Journal of Genetic Counseling. 
https://doi.org/10.1007/s10897-017-0170-z 
 
Rodriguez-Revenga, L., Madrigal, I., Pagonabarraga, J., Xunclà, M., Badenas, C., 
Kulisevsky, J., … Milà, M. (2009). Penetrance of FMR1 premutation associated 
pathologies in fragile X syndrome families. European Journal of Human Genetics: 
EJHG, 17(10), 1359–1362. https://doi.org/10.1038/ejhg.2009.51 
 
Saul, R. A., & Tarleton, J. C. (1993). FMR1-related disorders. In R. A. Pagon, M. P. Adam, 
H. H. Ardinger, S. E. Wallace, A. Amemiya, L. J. Bean, … K. Stephens 
(Eds.), GeneReviews (®). Seattle (WA): University of Washington, Seattle. 
Retrieved from http://www.ncbi.nlm.nih.gov/books/NBK1384/ 
 
Schneider, A., Hagerman, R. J., & Hessl, D. (2009). Fragile X syndrome -- from genes to 
cognition. Developmental Disabilities Research Reviews, 15(4), 333–342. 
https://doi.org/10.1002/ddrr.80 
 
Schwartz, C. E., Dean, J., Howard-Peebles, P. N., Bugge, M., Mikkelsen, M., Tommerup, 
N., … Stevenson, R. E. (1994). Obstetrical and gynecological complications in 
fragile X carriers: a multicenter study. American Journal of Medical 
Genetics, 51(4), 400–402. https://doi.org/10.1002/ajmg.1320510419 
 
Sherman, S., Pletcher, B. A., & Driscoll, D. A. (2005). Fragile X syndrome: diagnostic and 
carrier testing. Genetics in Medicine: Official Journal of the American College of 
Medical Genetics, 7(8), 584–587. 
https://doi.org/10.109701.GIM.0000182468.22666.dd 
 
Sidorov, M. S., Auerbach, B. D., & Bear, M. F. (2013). Fragile X mental retardation protein 
and synaptic plasticity. Molecular Brain, 6, 15. https://doi.org/10.1186/1756-6606-
6-15 
 
Sutcliffe, J. S., Nelson, D. L., Zhang, F., Pieretti, M., Caskey, C. T., Saxe, D., & Warren, 
S. T. (1992). DNA methylation represses FMR-1 transcription in fragile X 




Tassone, F., Hagerman, P. J., & Hagerman, R. J. (2014). Fragile x premutation. Journal of 
Neurodevelopmental Disorders, 6(1), 22. https://doi.org/10.1186/1866-1955-6-22 
 
Tassone, F., Iong, K. P., Tong, T.-H., Lo, J., Gane, L. W., Berry-Kravis, E., … Hagerman, 
R. J. (2012). FMR1 CGG allele size and prevalence ascertained through newborn 
screening in the United States. Genome Medicine, 4(12), 100. 
https://doi.org/10.1186/gm401 
 
Turner, G., Webb, T., Wake, S., Robinson, H. 1996. The prevalence of the fragile X 
syndrome. American Journal of Medical Genetics, (64), 196–197. 
 
Usdin, K., Hayward, B. E., Kumari, D., Lokanga, R. A., Sciascia, N., & Zhao, X.-N. 
(2014). Repeat-mediated genetic and epigenetic changes at the FMR1 locus in the 
Fragile X-related disorders. Frontiers in Genetics, 5, 226. 
https://doi.org/10.3389/fgene.2014.00226 
 
Verkerk, A. J., Pieretti, M., Sutcliffe, J. S., Fu, Y. H., Kuhl, D. P., Pizzuti, A., … Zhang, 
F. P. (1991). Identification of a gene (FMR-1) containing a CGG repeat coincident 
with a breakpoint cluster region exhibiting length variation in fragile X 
syndrome. Cell, 65(5), 905–914. 
 
Voorhuis, M., Onland-Moret, N. C., Janse, F., Ploos van Amstel, H. K., Goverde, A. J., 
Lambalk, C. B., … Dutch Primary Ovarian Insufficiency Consortium. (2014). The 
significance of fragile X mental retardation gene 1 CGG repeat sizes in the normal 
and intermediate range in women with primary ovarian insufficiency. Human 
Reproduction (Oxford, England), 29(7), 1585–1593. 
https://doi.org/10.1093/humrep/deu095 
 
Wheeler, A. C., Bailey, D. B., Berry-Kravis, E., Greenberg, J., Losh, M., Mailick, M., … 
Hagerman, R. (2014). Associated features in females with an FMR1 








ADVERTISEMENT FOR SOCIAL MEDIA
The following advertisement was posted on various Facebook groups. 
Hello, 
 
My name is Zahra Girnary and I am a genetic counseling student at the University of South 
Carolina. For my thesis project, I want to study individuals who lives are affected by fragile 
X syndrome, but do not have fragile X syndrome themselves. 
 
If you are a carrier of either a fragile X premutation allele or an intermediate/gray zone 
allele, please consider completing my questionnaire to study patients’ perceptions of 
clinical risk. I also want to learn which resources, if any, are most helpful to patients so 
that we can improve upon them and help the community at large. 
 
This questionnaire should take about 20 minutes to complete. 
https://www.surveymonkey.com/r/USC_FragileX 
 













FMR1 PREMUTATION SURVEY 
The following survey was distributed on various online Facebook groups and targeted 
individuals with the FMR1 premutation.  
Hello, 
 
Thank you for your interest in this study. You are being asked to participate in this 
research study because you are either a fragile X premutation allele carrier or a fragile X 
intermediate/gray zone allele carrier. Your participation in this study is completely 
voluntary and all responses are anonymous and will be kept confidential. Informed 
consent will be implied upon completion of the questionnaire, but you may stop your 
participation at any time or choose not to answer specific questions without any 
consequence, as some questions may touch on sensitive topics. 
 
The online questionnaire should take approximately 20 minutes to complete and there 
will be no course credit or monetary compensation given for your participation. However, 
your time is greatly appreciated and we hope the results will further research in the 
fragile X community. 
 
If you have any questions, please do not hesitate to contact me by email at 
zahra.girnary@uscmed.sc.edu. Additionally, if you would like to learn the results of the 





Genetic Counseling Student 
University of South Carolina – Columbia  
 
1) By clicking “Yes” I have read the above and choose to participate in this study. 
Yes 
 
2) I am a fragile X 
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Intermediate/Gray Zone Allele Carrier (41-54 CGG repeats) 
Premutation Allele Carrier (Between 55-200 CGG repeats) 
 
3) When you received your premutation result, what information did you receive 
from your healthcare provider about the implications for your own health? 
 
4) Has the size of your premutation affected your reproductive decisions? If so, how 
and why? 
 
5) If you have any family members diagnosed with fragile X syndrome, please list 
their relationship to you and approximate year of diagnosis in the space provided. 
 
6) When was the last time you had a formal discussion with your healthcare provider 




Between 1991 – 2017 
 
7) (If they select “Between 1991-2017”) Please select the year you had a formal 
discussion regarding fragile X syndrome and its implications with a healthcare 
provider. 
1991     2004     2017 
 
8) When were you found to be a premutation carrier? 
Unsure 
Before 1990 
Between 1991 – 2017 
 
9) (If they select “Between 1991-2017”) Please select the year you were found to be 
a premutation carrier. 
1991     2004     2017 
 
10) What was the indication for you being tested for a premutation? 
I have a child/children with fragile X syndrome 
I have a family history of fragile X syndrome 
I have a family member known to be a premutation carrier 
Prenatal carrier screening 
Other (please specify) 





11) (If they selected “Other” or “I have not been tested”) You selected “Other” or “I 
have not been tested”. Please explain your answer in the space provided below. 
 






The following questions are general knowledge questions about the inheritance of 
Fragile X syndrome. 
13) Who has the greatest chance of inheriting a fragile X premutation? 
Daughter of a male premutation carrier 
Daughter of a female premutation carrier 
Son of a male premutation carrier 
Son of a female premutation carrier 
All have the same chance 
Unsure 
 
14) Who has the greatest chance of having a child with fragile X syndrome? 
Female premutation carrier 
Male premutation carrier 
Both have the same chance of having a child with fragile X 
Unsure 
 
The following questions include conditions that are commonly observed in the 
general population. For each condition, please indicate how likely you believe the 
condition is to be observed in individuals who carry a fragile X premutation allele.  
 
1) What is the likelihood of a fragile X premutation allele causing heart disease in a 
premutation carrier? 
0  100% 
 
2) What is the likelihood of a fragile X premutation allele causing kidney problems 
in a premutation carrier? 




3) What is the likelihood of a fragile X premutation allele causing uterine fibroids in 
a premutation carrier? 
0  100% 
 
4) What is the likelihood of a fragile X premutation allele causing early menopause 
in a premutation carrier? 
0  100% 
 
5) What is the likelihood of a fragile X premutation allele causing diabetes in a 
premutation carrier? 
0  100% 
 
6) What is the likelihood of a fragile X premutation allele causing social anxiety in a 
premutation carrier? 
0  100% 
 
7) What is the likelihood of a fragile X premutation allele causing depression in a 
premutation carrier? 
0  100% 
 
8) What is the likelihood of a fragile X premutation allele causing tremor/ataxia in a 
premutation carrier? 
0  100% 
 
9) What is the likelihood of a fragile X premutation allele causing gastric reflux in a 
premutation carrier? 
0  100% 
 
10) What is the likelihood of a fragile X premutation allele causing glaucoma in a 
premutation carrier? 
0  100% 
 
The following questions are related to fragile-X-associated psychiatric 
manifestations. 
1) Psychiatric manifestations associated with being a carrier of the fragile X 











2) Approximately ________ percent of women carrying a fragile X premutation 













4) (If they selected “Unsure”) You selected “Unsure”, please explain in the space 
provided below. 
 






6) (If they selected “Unsure”) You selected “Unsure”, please explain in the space 
provided below. 
 
7) WHERE or FROM WHOM did you FIRST learn that psychiatric manifestations 
were associated with the fragile X premutation? 
This has never been discussed with me 
Do not know/recall 
Face to face support group 
Book(s) 
Conversations with other carriers of a fragile X premutation 
Internet website(s) (please specify what website)  
Online Facebook group (please specify which one) 
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Informational pamphlet (please specify from whom you received the 
pamphlet below) 
Conversations with healthcare providers (please specify what type) 
Other (please specify) 
For responses asking for additional information, please use the space provided 
below. 
 
8) WHEN did you FIRST learn that psychiatric manifestations were associated with 
the fragile X premutation? 
This has never been discussed with me 
At the time I was found to be a premutation carrier 
At the time of my mental health diagnosis 
At the time of a family member’s mental health diagnosis 
At the time of my child’s fragile X syndrome diagnosis 
At the time of another family member’s fragile X syndrome diagnosis 
At another time (please explain at what time below) 
Please explain when you found out that psychiatric manifestations were 
associated with the fragile X premutation. 
 
9) In the space provided, please describe when you believe is the best time for the 
healthcare provider to first discuss the association between fragile X syndrome 
and psychiatric manifestations with a carrier of a premutation. 
 
10) Choose THREE (3) resources you find the most helpful in learning about 
psychiatric manifestations associated with being a carrier of the fragile X 
premutation. 
Book(s) 
Face to face support group 
Conversations with other carriers of a fragile X premutation 
Conversations with healthcare providers (please specify what type) 
Internet website(s) (please specify what website) 
Online Facebook group (please specify which group) 
Informational pamphlet (please specify from whom you received the 
pamphlet below) 
Other (please specify) 





11) In the space provided below please list any suggestions for genetic counseling for 
psychiatric manifestations associated with being a carrier of the fragile X 
premutation. 
 
The following questions are related to fragile-X-associated primary ovarian 
insufficiency (FXPOI). 
 
1) Fragile X-associated primary ovarian insufficiency (FXPOI), previously known as 
premature ovarian failure (POF), can involve which of the following (select all 
that apply): 
Menstrual cycle irregularities 
Hormone fluctuations 
Decreased fertility 
Early onset menopause 
Osteoporosis 
 














4) (If they selected “Unsure”) You selected “Unsure”. Please explain in the space 
provided below 
 









7) WHERE or FROM WHOM did you first learn that POI/POF was associated with 
the fragile X premutation? 
This has never been discussed with me 
Do not know/recall 
Face to face support group 
Book(s) 
Conversations with other carriers of a fragile X premutation 
Internet website(s) (please specify what website) 
Online Facebook groups (please specify which one) 
Informational pamphlet (please specify from whom you received the 
pamphlet below) 
Conversations with healthcare providers (please specify what type) 
Other (please specify) 
For responses asking for additional information, please use the space provided 
below. 
 
8) WHEN did you first learn that POI/POF was associated with the fragile X 
premutation? 
This has never been discussed with me 
At the time I was found to be a premutation carrier 
At the time of my POI/POF diagnosis 
At the time of a family member’s POI/POF diagnosis 
At the time of my child’s fragile X syndrome diagnosis 
At the time of another family member’s fragile X syndrome diagnosis 
At another time (please explain at what time below) 
If you selected “At another time”, please explain in the space provided below. 
9) In the space provided below, please describe when you believe is the best time for 
the healthcare provider to first discuss the association between fragile X 
syndrome and FXPOI/POF with a carrier of a premutation. 
 
10) Choose THREE (3) resources you find the most helpful in learning about 
psychiatric manifestations associated with being a carrier of the fragile X 
premutation. 
Book(s) 
Face to face support group 
Conversations with other carriers of a fragile X premutation 
Conversations with healthcare providers (please specify what type) 
Internet website(s) (please specify what website) 
Online Facebook group (please specify which group) 
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Informational pamphlet (please specify from whom you received the 
pamphlet below) 
Other (please specify) 
For responses asking for additional information, please use the space provided 
below. 
11) In the space provided below, please list any suggestions for genetic counseling for 
FXPOI/POF. 
 
The following questions are related to fragile-X-associated tremor/ataxia syndrome 
(FXTAS). 
1) Fragile X-associated tremor/ataxia syndrome (FXTAS) can involve which of the 




Difficulty with balance 
Difficulty walking 
Numbness in extremities 
 













4) (If they selected “Unsure”) You selected “Unsure”. Please explain in the space 
provided below 
 






6) (If they selected “Unsure”) You selected “Unsure”. Please explain in the space 
provided below 
 
7) WHERE or FROM WHOM did you first learn that tremor/ataxia was associated 
with the Fragile X premutation? 
This has never been discussed with me 
Do not know/recall 
Face to face support group 
Book(s) 
Conversations with other carriers of a fragile X premutation 
Internet website(s) (please specify what website)  
Online Facebook group (please specify which one) 
Informational pamphlet (please specify from whom you received the 
pamphlet below) 
Conversations with healthcare providers (please specify what type) 
Other (please specify) 
For responses asking for additional information, please use the space provided 
below. 
8) WHEN did you first learn that tremor/ataxia was associated with the fragile X 
premutation? 
This has never been discussed with me 
At the time I was found to be a premutation carrier 
At the time of my POI/POF diagnosis 
At the time of a family member’s POI/POF diagnosis 
At the time of my child’s fragile X syndrome diagnosis 
At the time of another family member’s fragile X syndrome diagnosis 
At another time (please explain at what time below) 
Please explain when you found out that FXTAS was associated with the fragile X 
premutation. 
 
9) In the space provided below, please describe when you believe is the best time for 
the healthcare provider to first discuss the association between fragile X 
syndrome and FXTAS with a carrier of a premutation. 
 
10) Choose THREE (3) resources you find the most helpful in learning about 
psychiatric manifestations associated with being a carrier of the fragile X 
premutation. 
Book(s) 
Face to face support group 
Conversations with other carriers of a fragile X premutation 
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Conversations with healthcare providers (please specify what type) 
Internet website(s) (please specify what website) 
Online Facebook group (please specify which group) 
Informational pamphlet (please specify from whom you received the 
pamphlet below) 
Other (please specify) 
For responses asking for additional information, please use the space provided. 








2) I am ______ years old. 
 
3) I live_______________. 
In the United States  
Outside the United States  
 
4) (If they choose “In the United States”) Which state do you live in? 
 
5) (If they choose “Outside the United States”) Which country do you live in? 
 
6) What is your highest level of education? 
Less than high school 
Some high school 
High school diploma or equivalent 
Some college, vocational or trade school 
College degree 
Graduate or professional degree (please specify) 
 
7) (If they selected “Graduate or Professional Degree”) What is your graduate or 
professional degree (i.e., MS, PhD, MD, JD, etc.)? 
 




9) In the space provided below, please indicate the website or listserv where you 
learned about this survey 
 
10) If you’d like to receive the results of this study, please provide your email address 





FMR1 INTERMEDIATE/GRAY ZONE ALLELE SURVEY 
The following survey was distributed on various online Facebook groups and targeted 
individuals with the FMR1 intermediate/gray zone allele.  
Hello, 
 
Thank you for your interest in this study. You are being asked to participate in this 
research study because you are either a fragile X premutation allele carrier or a fragile X 
intermediate/gray zone allele carrier. Your participation in this study is completely 
voluntary and all responses are anonymous and will be kept confidential. Informed 
consent will be implied upon completion of the questionnaire, but you may stop your 
participation at any time or choose not to answer specific questions without any 
consequence, as some questions may touch on sensitive topics. 
 
The online questionnaire should take approximately 20 minutes to complete and there 
will be no course credit or monetary compensation given for your participation. However, 
your time is greatly appreciated and we hope the results will further research in the 
fragile X community. 
 
If you have any questions, please do not hesitate to contact me by email at 
zahra.girnary@uscmed.sc.edu. Additionally, if you would like to learn the results of the 





Genetic Counseling Student 
University of South Carolina – Columbia  
 
1) By clicking “Yes” I have read the above and choose to participate in this study. 
Yes 
 
2) I am a fragile X 
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Intermediate/Gray Zone Allele Carrier (41-54 CGG Units) 
Premutation Allele Carrier (55-200 CGG Units) 
 
3) When you received your gray zone/intermediate allele result, what information 
did you receive from your healthcare provider about the implications for your 
own health? 
 
4) If you have any family members diagnosed with fragile X syndrome, please list 
their relationship to you and approximate year of diagnosis in the space provided. 
 
5) When was the last time you had a formal discussion with your healthcare provider 
regarding fragile X syndrome and its implications? 




Between 1991 – 2017 
 
6) (If they select “Between 1991-2017”) Please select the year you had a formal 
discussion regarding fragile X syndrome and its implications with a healthcare 
provider. 
1991     2004     2017 
 
7) When were you found to be an intermediate/gray zone allele carrier? 
Unsure 
Before 1990 
Between 1991 – 2017 
 
8) (If they select “Between 1991-2017”) Please select the year you were found to be 
an intermediate/gray zone allele carrier. 
1991     2004     2017 
 
9) What was the indication for you being tested for fragile X? 
I have a child/children with fragile X syndrome 
I have a family history of fragile X syndrome 
I have a family member known to be a premutation carrier 
Prenatal carrier screening 
Other (please specify) 




10) (If they selected “Other” or “I have not been tested”) You selected “Other” or “I 
have not been tested”. Please explain your answer in the space provided below. 
 






12) Have you or anyone in your family been diagnosed with Parkinson’s Disease? 
 





Parkinsonism (Defined as having 2 of the following: bradykinesia, resting 





14) Has your gray zone result affected your reproductive decisions? If so, how and 
why? 
 
15) There exist many online support groups for individuals with fragile X syndrome 
as well as those who are premutation allele carriers. How likely would you be to 
access a support group for gray zone/intermediate allele carriers?  
Very unlikely   Unsure  Likely  Very likely 
16) (If they answered “Likely” or “Very Likely”) You answered “Likely” or “Very 
Likely” in the previous question. “How do you think a support group would 
benefit you?”  
 
The following questions are general knowledge questions about the inheritance of 
Fragile X syndrome. 
17) Who has the greatest chance of inheriting a fragile X premutation? 
Daughter of a male premutation carrier 
Daughter of a female premutation carrier 
Son of a male premutation carrier 
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Son of a female premutation carrier 
All have the same chance 
Unsure 
 
18) Who has the greatest chance of having a child with fragile X syndrome? 
Female premutation carrier 
Male premutation carrier 
Both have the same chance of having a child with fragile X 
Unsure 
 
The following questions include conditions that are commonly observed in the 
general population. For each condition, please indicate how likely you believe the 
condition is to be observed in individuals who carry a Fragile X intermediate allele. 
An intermediate allele is defined as having between 41 and 54 CGG units. 
 
1) What is the likelihood of a fragile X intermediate allele causing heart disease in 
an intermediate allele carrier? 
0  100% 
2) What is the likelihood of a fragile X intermediate allele causing kidney problems 
in an intermediate allele carrier? 
0  100% 
 
3) What is the likelihood of a fragile X intermediate allele causing uterine fibroids in 
an intermediate allele carrier? 
0  100% 
 
4) What is the likelihood of a fragile X intermediate allele causing early menopause 
in an intermediate allele carrier? 
0  100% 
 
5) What is the likelihood of a fragile X intermediate allele causing diabetes in an 
intermediate allele carrier? 
0  100% 
 
6) What is the likelihood of a fragile X intermediate allele causing social anxiety in 
an intermediate allele carrier? 
0  100% 
 
7) What is the likelihood of a fragile X intermediate allele causing depression in an 
intermediate allele carrier? 
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0  100% 
 
8) What is the likelihood of a fragile X intermediate allele causing tremor/ataxia in 
an intermediate allele carrier? 
0  100% 
 
9) What is the likelihood of a fragile X intermediate allele causing gastric reflux in 
an intermediate allele carrier? 
0  100% 
 
10) What is the likelihood of a fragile X intermediate allele causing glaucoma in an 
intermediate allele carrier? 
0  100% 
 
Demographic Questions 




20) I am ______ years old. 
 
21) I live_______________. 
In the United States  
Outside the United States  
 
22) (If they choose “In the United States”) Which state do you live in? 
 
23) (If they choose “Outside the United States”) Which country do you live in? 
 
24) What is your highest level of education? 
Less than high school 
Some high school 
High school diploma or equivalent 
Some college, vocational or trade school 
College degree 
Graduate or professional degree (please specify) 
 
25) (If they selected “Graduate or Professional Degree”) What is your graduate or 




26) What is your occupation? 
 
27) In the space provided below, please indicate the website or listserv where you 
learned about this survey 
 
28) If you’d like to receive the results of this study, please provide your email address 





















SURVEY DEBRIEFING FORM 
For participants in the United States: 
Thank you for agreeing to participate in this research. You may find the nature of some 
of the questions to be personal and/or sensitive.  If you feel that you may benefit from 
psychological services, there are options available.  
 
One option is to seek either treatment or an appropriate referral from either your primary 
care physician or personal psychologist. You may also contact the national crisis hotline 
at (775) 784-8090 or the National Suicide Prevention Hotline at 1 (800) 273-8255.  
 
If you ever feel as though you may be a danger to yourself or others, it is important 
that you seek help immediately. If your emergency takes place after business hours, 
please call 911 or go to the emergency room of your nearest hospital. 
 
For international participants:  
Thank you for agreeing to participate in this research. You may find the nature of some 
of the questions to be personal and/or sensitive.  If you feel that you may benefit from 
psychological services, there are options available.  
 
One option is to seek either treatment or an appropriate referral from either your primary 
care physician or personal psychologist. You may also wish to visit the International 
Association for Suicide Prevention (IASP) at 
http://www.iasp.info/resources/Crisis_Centres/ and/or BetterHelp at 
https://www.betterhelp.com/gethelpnow/ to find a crisis center near you. 
 
If you ever feel as though you may be a danger to yourself or others, it is important 
that you seek help immediately. If your emergency takes place after business hours, 
please call your local emergency number or go to the emergency room of your 
nearest hospital. 
 
 
